<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunol Res</journal-id><journal-id journal-id-type="iso-abbrev">J Immunol Res</journal-id><journal-id journal-id-type="publisher-id">JIR</journal-id><journal-title-group><journal-title>Journal of Immunology Research</journal-title></journal-title-group><issn pub-type="ppub">2314-8861</issn><issn pub-type="epub">2314-7156</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2018/6718083</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0754-8664</contrib-id><name><surname>Adhikari</surname><given-names>Utpal Kumar</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8664-6918</contrib-id><name><surname>Tayebi</surname><given-names>Mourad</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4225-9451</contrib-id><name><surname>Rahman</surname><given-names>M. Mizanur</given-names></name><email>mmrahmanbtg79@hotmail.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia 7003, Bangladesh</aff><aff id="I2">
<sup>2</sup>School of Medicine, Western Sydney University, Campbelltown, NSW, Australia</aff><author-notes><fn fn-type="other"><p>Academic Editor: Nejat K. Egilmez</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>8</day><month>10</month><year>2018</year></pub-date><volume>2018</volume><elocation-id>6718083</elocation-id><history><date date-type="received"><day>16</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Utpal Kumar Adhikari et al.</copyright-statement><copyright-year>2018</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Oropouche virus (OROV) is an emerging pathogen which causes Oropouche fever and meningitis in humans. Several outbreaks of OROV in South America, especially in Brazil, have changed its status as an emerging disease, but no vaccine or specific drug target is available yet. Our approach was to identify the epitope-based vaccine candidates as well as the ligand-binding pockets through the use of immunoinformatics. In this report, we identified both T-cell and B-cell epitopes of the most antigenic OROV polyprotein with the potential to induce both humoral and cell-mediated immunity. Eighteen highly antigenic and immunogenic CD8<sup>+</sup> T-cell epitopes were identified, including three 100% conserved epitopes (<italic>TSSWGCEEY</italic>, <italic>CSMCGLIHY</italic>, and <italic>LAIDTGCLY</italic>) as the potential vaccine candidates. The selected epitopes showed 95.77% coverage for the mixed Brazilian population. The docking simulation ensured the binding interaction with high affinity. A total of five highly conserved and nontoxic linear B-cell epitopes &#x0201c;<italic>NQKIDLSQL</italic>,&#x0201d; &#x0201c;<italic>HPLSTSQIGDRC</italic>,&#x0201d; &#x0201c;<italic>SHCNLEFTAITADKIMSL</italic>,&#x0201d; &#x0201c;<italic>PEKIPAKEGWLTFSKEHTSSW</italic>,&#x0201d; and &#x0201c;<italic>HHYKPTKNLPHVVPRYH</italic>&#x0201d; were selected as potential vaccine candidates. The predicted eight conformational B-cell epitopes represent the accessibility for the entered virus. In the posttherapeutic strategy, ten ligand-binding pockets were identified for effective inhibitor design against emerging OROV infection. Collectively, this research provides novel candidates for epitope-based peptide vaccine design against OROV.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Oropouche virus (OROV) is the most common Orthobunyavirus of the Bunyaviridae family, an important causative agent of Oropouche fever in human widespread in South America, especially in Brazil. This fever is clinically characterized as an acute febrile urban arboviral disease [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. Oropouche fever causes a dengue-like illness with sudden onset of high fever (upwards of 105&#x000b0;F/41&#x000b0;C), headache, malaise, myalgia, arthralgia, nausea, vomiting, and dizziness, allied with viremia in the early five to six days. Usually, the patients recover within two to three weeks without any apparent sequel or death [<xref rid="B3" ref-type="bibr">3</xref>]. In some patients, OROV can cause viral meningitis with skin rash, neck stiffness, and photophobia [<xref rid="B4" ref-type="bibr">4</xref>]. The OROV can enter into the central nervous system (CNS) and can spread into the brain parenchyma tissue through some infective cycles. Lastly, it causes inflammation and severe manifestations of encephalitis [<xref rid="B5" ref-type="bibr">5</xref>]. In spite of its clinical relevance to public health, very little is known about the pathogenesis of OROV in humans and in other vertebrate animals. Proenca-Modena and coworkers demonstrated that the MAVS (mitochondrial antiviral-signaling protein), IRF-3 (interferon regulatory transcription factor) and IRF-7, and MAVS-dependent type I IFN signaling pathway (IFNAR) have dominant roles in restricting OROV infection, and this signaling in nonmyeloid cells greatly contributes to the host defense against orthobunya viruses [<xref rid="B6" ref-type="bibr">6</xref>].</p><p>OROV was first isolated from the blood of a febrile forest worker in Trinidad &#x00026; Tobago in 1955. The second strain of OROV was isolated and collected from the pool of 177 <italic>Coquillettidia venezuelensis</italic> mosquitoes in Trinidad in 1960 [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>]. Several outbreaks have been recorded in the South Americas, from both urban and rural people of Brazil, Panama, Peru, Ecuador, and Trinidad &#x00026; Tobago [<xref rid="B2" ref-type="bibr">2</xref>]. The virus is deliberated as a public health threat in tropical and subtropical areas of Central and South America, with thirty outbreaks and over half a million (500,000) infected people as of 2005. In 2009, OROV reemerged in the municipalities of Altamira and Santa Barbara, Par&#x000e1; State, and subsequently in Mazag&#x000e3;o in the state of Amap&#x000e1;, Brazil [<xref rid="B1" ref-type="bibr">1</xref>].</p><p>The virus is a single-stranded negative-sense and three-segmented RNA virus. These three segments are large (L), medium (M), and small (S), which encodes the viral RNA-dependent RNA polymerase, the surface glycoproteins (Gn and Gc), and the nucleocapsid (N) protein, respectively [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. Initially, the partial genome was sequenced for the Brazilian prototype OROV strain BeAn19991, and the complete and corrected genome sequences of the three segments, especially the M segment, were published in 2015 [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. The M segment comprises a single ORF which encodes a large polyprotein that is cleaved during or after the translation and produces a nonstructural protein (NSm), and two structural surface glycoproteins (Gn and Gc) [<xref rid="B2" ref-type="bibr">2</xref>]. These glycoproteins Gn and Gc help in the interaction between the virus particle and the cell receptor. According to Tilston-Lunel et al., the nonstructural protein (NSm) of the M segment is unessential for virus replication in the mosquito and mammalian cell lines [<xref rid="B10" ref-type="bibr">10</xref>]. Based on the S segment genetic information, the OROV can consist of four major genotypes (I, II, III, and IV), and Brazil is the main geographical region of these four genotypes [<xref rid="B2" ref-type="bibr">2</xref>]. The transmission of OROV is maintained in nature by two distinct cycles such as sylvatic and urban [<xref rid="B12" ref-type="bibr">12</xref>]. <italic>Bradypus tridactylus</italic> (sloth), some wild birds, and nonhuman primates (NHPs) control the sylvatic cycle, whereas the urban cycle is maintained only by humans [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B8" ref-type="bibr">8</xref>]. In humans, the OROV is transmitted by the midge <italic>(Culicoides paraensis)</italic> and the mosquito <italic>(Culex p. quinquefasciatus)</italic>, but no evidence for direct transmission from human to human has ever been recorded [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Diagnosis of OROV infection is performed by using various types of classic methods such as virus isolation and cell culture and molecular techniques such as serologic assays (CF, HI, and NT tests and in-house enzyme-linked immunosorbent assay) and real-time polymerase chain reaction (RT-PCR) in acute samples for genome detection [<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>].</p><p>Before 2016, there were no reports of the occurrence of Oropouche fever in humans in Goi&#x000e2;nia city, the State of Goi&#x000e1;s, and central Brazil. But the OROV antibody has been found in NHPs in Goi&#x000e2;nia city [<xref rid="B17" ref-type="bibr">17</xref>]. So, immunity development in NHPs against this OROV should be taken into consideration as a vital warning sign of ongoing virus circulation.</p><p>Since effective and specific commercial rapid diagnostic tests are unavailable, there are great concerns for its possible future outbreaks similar to Zika in South American countries, especially in Brazil. Furthermore, there is no specific approved drug or vaccine against OROV available in the market. Although the role of the MAVS-dependent type I IFN signaling pathway has been shown to control OROV replication [<xref rid="B6" ref-type="bibr">6</xref>], it is not enough to completely eradicate OROV from the system. In this situation, adaptive immunity development against OROV could play an effective role in the complete elimination of the virus. Adaptive immunity works based on the recognition of specific epitopes by T-cells after reinfection. Consequently, humoral immune response is activated in humans.</p><p>In the present study, we have analyzed the complete proteome of the OROV for the identification of the most antigenic protein and its highest immunogenic and antigenic T-cell epitopes along with B-cell epitopes for the development of the epitope-based peptide vaccine using immunoinformatic approaches. We have also predicted the 3D structure of the most antigenic polyprotein as well as inhibitor-binding sites for the docking simulation study using various bioinformatics tools. Ultimately, this study is aimed at assisting the future laboratory efforts in developing effective vaccination for the prevention of OROV infection.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><p>The flow chart representing the overall procedures of epitope-based vaccine design and ligand-binding pocket prediction for OROV polyprotein and is illustrated in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><sec id="sec2.1"><title>2.1. Retrieval of the Target Sequence</title><p>The FASTA formatted amino acid sequences of OROV were retrieved from the Virus Pathogen Database and Analysis Resource (ViPR) (<ext-link ext-link-type="uri" xlink:href="http://www.viprbrc.org/">http://www.viprbrc.org/</ext-link>), an integrated, powerful resource for several virus families and their respective species [<xref rid="B18" ref-type="bibr">18</xref>]. This database is integrated with the National Center for Biotechnology Information (NCBI) as well as UniProtKB database and helps to download the FASTA formatted sequence from both GenBank and UniProtKB. In this study, the nonstructural proteins (NSPs) were excluded from the total proteome of OROV. So, a total available 21 polymerase, 6 glycoprotein, 39 nucleocapsids, 20 polyproteins, and 46 nucleoprotein sequences were primarily selected for antigenicity prediction.</p></sec><sec id="sec2.2"><title>2.2. Highest Antigenic Protein Identification</title><p>To uncover the highest antigenic protein, the FASTA formatted amino acid sequences of total structural proteins were submitted to the VaxiJen v2.0 server (<ext-link ext-link-type="uri" xlink:href="http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html">http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html</ext-link>) for antigenicity prediction [<xref rid="B19" ref-type="bibr">19</xref>]. This approach led to the selction of the highly antigenic protein for further analysis.</p></sec><sec id="sec2.3"><title>2.3. T-Cell Epitope Identification</title><p>The T-cell epitopes are typically peptide fragments which are immunodominant and can elicit specific immune responses, important for epitope-based peptide vaccine design. Due to the importance of T-cell epitopes, the NetCTL 1.2 server was used for the prediction of cytotoxic T-lymphocyte (CTL) epitopes derived from the protein sequence. The NetCTL 1.2 server (<ext-link ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/NetCTL/">http://www.cbs.dtu.dk/services/NetCTL/</ext-link>) can predict human CTL epitopes in any given protein. The NetCTL 1.2 server can predict CD8<sup>+</sup> T-cell epitopes for 12 supertypes such as A1, A2, A3, A24, A26, B7, B8, B27, B39, B44, B58, and B62 taking into account the proteasomal C terminal cleavage, MHC class I binding, and TAP transport efficiency. MHC class I binding, proteasomal C terminal cleavage, and TAP transport efficiency are predicted using artificial neural networks and the weight matrix, respectively [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. We identified epitopes for all the 12 supertypes. In this study, the threshold value for epitope identification was set at 1.25 which has a sensitivity and specificity of 0.54 and 0.993, respectively. The weight on C terminal cleavage and TAP transport efficiency were used as default parameters. Initially, 128 epitopes were selected based on the highest combined score, but the final selection completed after the antigenicity and immunogenicity prediction of the epitopes through the VaxiJen v2.0 server and IEDB server, respectively.</p><p>For the identification of both frequently and nonfrequently occurring MHC-I-binding alleles, the epitopes were analyzed by the stabilized matrix base method (SMM) in the IEDB analysis tool (<ext-link ext-link-type="uri" xlink:href="http://tools.iedb.org/mhci/">http://tools.iedb.org/mhci/</ext-link>) [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>]. The amino acid length of peptide 9.0 and the IC50 value less than 200 were selected as parameters for the identification of MHC-I-binding alleles. Here, peptides with IC50 values &#x0003c; 50&#x02009;nM are considered as high affinity, &#x0003c;500&#x02009;nM intermediate affinity, and &#x0003c;5000&#x02009;nM low affinity. So, the lower IC50 value indicates higher affinity. IEDB is a resourceful server, and this server was also used for the prediction of processing score, proteasomal cleavage, TAP score, and the MHC-I-binding score of the selected epitopes and their respective alleles using the SMM [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>]. The SMM-align method was used for the prediction of MHC-II-binding alleles of the best candidate epitope [<xref rid="B26" ref-type="bibr">26</xref>].</p></sec><sec id="sec2.4"><title>2.4. Epitope Conservancy and Immunogenicity Prediction</title><p>For epitope conservancy and immunogenicity prediction, the conservancy (<ext-link ext-link-type="uri" xlink:href="http://tools.iedb.org/conservancy/">http://tools.iedb.org/conservancy/</ext-link>) and immunogenicity (<ext-link ext-link-type="uri" xlink:href="http://tools.iedb.org/immunogenicity/">http://tools.iedb.org/immunogenicity/</ext-link>) prediction tools of IEDB were used [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>]. The conservancy indicates the specific portion of a protein sequence that restrains the epitope and shows availability with a specific level of identity. More immunogenic peptides are superior to the less immunogenic peptides and considered as effective T-cell epitopes. So, the epitope with high immunogenicity was selected for further analysis.</p></sec><sec id="sec2.5"><title>2.5. Prediction of Population Coverage</title><p>We used the IEDB population coverage tool (<ext-link ext-link-type="uri" xlink:href="http://tools.iedb.org/population/">http://tools.iedb.org/population/</ext-link>) for the analysis of the population coverage of the predicted epitopes and their respective MHC HLA-binding alleles [<xref rid="B28" ref-type="bibr">28</xref>].</p></sec><sec id="sec2.6"><title>2.6. Allergenicity and Toxicity Extrapolation</title><p>Allergenicity was anticipated through AllerTOP v. 2.0 (<ext-link ext-link-type="uri" xlink:href="http://www.ddg-pharmfac.net/AllerTOP/">http://www.ddg-pharmfac.net/AllerTOP/</ext-link>) [<xref rid="B28" ref-type="bibr">28</xref>] and AllergenFP 1.0 (<ext-link ext-link-type="uri" xlink:href="http://www.ddg-pharmfac.net/AllergenFP/">http://www.ddg-pharmfac.net/AllergenFP/</ext-link>) [<xref rid="B29" ref-type="bibr">29</xref>]. AllergenFP 1.0 has been developed based on a novel alignment-free descriptor-based fingerprint approach. AllergenFP 1.0 can identify both allergens and nonallergens with 87.9% accuracy [<xref rid="B29" ref-type="bibr">29</xref>]. On the other hand, AllerTOP v. 2.0 is a robust and strong complimentary approach which has been developed based on the method, <italic>k</italic>-nearest neighbours (<italic>k</italic>NN), to classify allergens and nonallergens. The comparison among different allergen prediction servers designates that AllerTOP v. 2.0 is the best-performing method with 88.7% accuracy which is followed by AllergenFP 1.0 (87.9%) [<xref rid="B28" ref-type="bibr">28</xref>]. The toxicity of the peptides was predicted through the ToxinPred (<ext-link ext-link-type="uri" xlink:href="http://www.imtech.res.in/raghava/toxinpred/">http://www.imtech.res.in/raghava/toxinpred/</ext-link>) web server [<xref rid="B30" ref-type="bibr">30</xref>]. This method was developed based on the machine learning technique and quantitative matrix using different properties of peptides.</p></sec><sec id="sec2.7"><title>2.7. Three-Dimensional Structure Design of the Best Epitope</title><p>After analyzing the conservancy of epitopes, combined score, antigenicity, immunogenicity, nontoxicity, and the availability of alleles, we identified the candidate epitopes <sup>1043</sup>TSSWGCEEY<sup>1051</sup> and <sup>4</sup>LAIDTGCLY<sup>12</sup> and submitted to the PEP-FOLD peptide structure prediction server (<ext-link ext-link-type="uri" xlink:href="http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/">http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/</ext-link>) at the Ressource Parisienne en Bioinformatique Structurale Mobyle Portal [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>]. We used the best model for analysis of the interaction with MHC-I- and MHC-II-binding alleles.</p></sec><sec id="sec2.8"><title>2.8. Docking Simulation Study</title><p>To know the interaction between binding alleles and predicted epitope, the molecular docking simulation study was performed using AutoDockTools [<xref rid="B33" ref-type="bibr">33</xref>] and AutoDock Vina software [<xref rid="B34" ref-type="bibr">34</xref>]. For this purpose, the crystal structure of the HLA-B<sup>&#x02217;</sup>35:01 protein molecule named 3LKR was retrieved from the RCSB Protein Data Bank (PDB) as the PDB format [<xref rid="B35" ref-type="bibr">35</xref>]. However, the predicted crystal structure was in a complex form with protein and an epitope. So, the Discovery Studio (version 16.1.0.15350) was used to simplify the complex structure. After the separation, the protein molecule and the peptide (epitope) were then converted to PDBQT format through AutoDockTools. For the identification of binding energy at the binding groove of HLA-B<sup>&#x02217;</sup>35:01 with an epitope, the space box center was set at 4.496, &#x02212;12.428, and &#x02212;35.544&#x02009;&#x000c5; in the <italic>X</italic>, <italic>Y</italic>, and <italic>Z</italic> axes, respectively. The size was set at 30, 24, and 18&#x02009;&#x000c5; in the <italic>X</italic>, <italic>Y</italic>, and <italic>Z</italic> dimensions, respectively, and these analyses were done at a 0.964&#x02009;&#x000c5; spacing parameter. Finally, the docking simulation was performed by using AutoDock Vina.</p><p>Another docking study was performed as a control for the critical evaluation and scientific acceptance of our docking study. The docking method and parameters were set just like the previously mentioned parameters so that we can easily compare between sample and control. In the control section, the docking simulation was completed between influenza NP418 epitope from the 2009 strain and the HLA-B<sup>&#x02217;</sup>35:01 protein molecule. The docking parameters for HLA-DR and the selected epitope were set at 20.066, 31.590, and 29.302&#x02009;&#x000c5; in the <italic>X</italic>, <italic>Y</italic>, and <italic>Z</italic> axes, respectively, and the size was set at 24, 36, and 18&#x02009;&#x000c5; in the <italic>X</italic>, <italic>Y</italic>, and <italic>Z</italic> dimensions, respectively. This docking was completed at a 0.769&#x02009;&#x000c5; spacing parameter.</p></sec><sec id="sec2.9"><title>2.9. Prediction of B-Cell Epitopes</title><p>B-cell epitope identification is the vital step for epitope-based peptide vaccine design. So, the B-cell epitopes were identified from the highest antigenic protein through the online BepiPred-2.0 (<ext-link ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/BepiPred/">http://www.cbs.dtu.dk/services/BepiPred/</ext-link>) [<xref rid="B36" ref-type="bibr">36</xref>] and LBtope methods (<ext-link ext-link-type="uri" xlink:href="http://crdd.osdd.net/raghava//lbtope/">http://crdd.osdd.net/raghava//lbtope/</ext-link>) [<xref rid="B37" ref-type="bibr">37</xref>]. BepiPred-2.0 has been developed based on the random forest algorithm which was trained on epitopes annotated from antigen-antibody protein structures. BepiPred-2.0 can be considered as the best and up-to-date B-cell epitope prediction method because it shows significant results both on epitope data derived from a large collection of linear epitopes taken from the IEDB database and on crystallography-derived structural epitope data [<xref rid="B36" ref-type="bibr">36</xref>]. LBtope is another powerful tool for linear B-cell epitope prediction which has been developed based on the experimentally validated non B-cell epitopes obtained from the IEDB database [<xref rid="B37" ref-type="bibr">37</xref>]. The Lbtope_confirm dataset, the amino acid length 15-mer, and the scoring threshold of 60% were selected as the parameters for the prediction of linear B-cell epitopes in the LBtope server.</p><p>The conformational or discontinuous B-cell epitopes were predicted by using the IEDB conformational B-cell prediction tool ElliPro (<ext-link ext-link-type="uri" xlink:href="http://tools.iedb.org/ellipro/">http://tools.iedb.org/ellipro/</ext-link>) [<xref rid="B38" ref-type="bibr">38</xref>]. The conformational B-cell epitope is the sequence of amino acid or subunits which comprise an antigen and can come in direct interaction with a receptor of the immune system. However, ElliPro is the most comprehensive method because it can predict both the linear and conformational epitopes based on a protein 3D structure and showed the score as a PI (protrusion index) value [<xref rid="B38" ref-type="bibr">38</xref>]. The parameters for conformational epitope prediction were set at 0.8 and 7&#x02009;&#x000c5; for a minimum score and maximum distance (Angstrom), respectively.</p></sec><sec id="sec2.10"><title>2.10. Ligand-Binding Pocket Prediction</title><p>For the assessment of various physiological and physicochemical properties of the selected most antigenic OROV polyprotein, different Bioinformatics tools such as ExPASy ProtParam tools (<ext-link ext-link-type="uri" xlink:href="https://web.expasy.org/protparam/">https://web.expasy.org/protparam/</ext-link>) and the PSIPRED (<ext-link ext-link-type="uri" xlink:href="http://bioinf.cs.ucl.ac.uk/psipred/">http://bioinf.cs.ucl.ac.uk/psipred/</ext-link>) server were used. ExPASy ProtParam [<xref rid="B39" ref-type="bibr">39</xref>] was used for the prediction of amino acid composition, molecular weight, extinction coefficient, isoelectric point (pI), instability index, aliphatic index, and grand average hydropathicity (GRAVY) value. The secondary structural properties such as alpha helix, extended strands, and random coils were predicted through the PSIPRED server [<xref rid="B40" ref-type="bibr">40</xref>]. DISOPRED3, an integrated tool of the PSIPRED server, was used for the enumeration of disordered regions or disease-causing regions [<xref rid="B41" ref-type="bibr">41</xref>]. The I-TASSER server (<ext-link ext-link-type="uri" xlink:href="https://zhanglab.ccmb.med.umich.edu/I-TASSER/">https://zhanglab.ccmb.med.umich.edu/I-TASSER/</ext-link>), a unified platform for automated protein structure prediction [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>], was used for the design of the three-dimensional (3D) structure of the OROV polyprotein. The predicted best model was refined two times by using the ModRefiner Server (<ext-link ext-link-type="uri" xlink:href="https://zhanglab.ccmb.med.umich.edu/ModRefiner/">https://zhanglab.ccmb.med.umich.edu/ModRefiner/</ext-link>) [<xref rid="B44" ref-type="bibr">44</xref>] and further refined by the Swiss-PdbViewer version 4.1.0 [<xref rid="B45" ref-type="bibr">45</xref>] with a harmonic constraint of 20&#x02009;kJ/mol/&#x000c5;<sup>2</sup>. This energy score was applied to all protein atoms, using the steepest descent and conjugate gradient method to reduce the bad contacts between protein atoms and structural water molecules. Computations were done in vacuo with the GROMOS96 43B1 parameter set, without reaction field implementation of Swiss-PdbViewer. To validate the protein model, we used different evaluation tools such as ProSA [<xref rid="B46" ref-type="bibr">46</xref>], QMEAN [<xref rid="B47" ref-type="bibr">47</xref>], and the ProQ server [<xref rid="B48" ref-type="bibr">48</xref>]. The stereochemical property of the predicted protein model was checked using PROCHECK through the PDBsum server [<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>]. Finally, the refined and evaluated protein structure was submitted to the PMDB database (<ext-link ext-link-type="uri" xlink:href="https://bioinformatics.cineca.it/PMDB/">https://bioinformatics.cineca.it/PMDB/</ext-link>) [<xref rid="B51" ref-type="bibr">51</xref>] for a unique accession identity number. The hydrophobicity properties of the protein were calculated through the Discovery Studio (version 16.1.0.15350).</p><p>The active site or ligand-binding site analyses make a clear perception of the molecular docking simulation study. The binding pockets of the OROV polyprotein structure were explored by the SiteHound-web (<ext-link ext-link-type="uri" xlink:href="http://scbx.mssm.edu/sitehound/sitehound-web/Input.html">http://scbx.mssm.edu/sitehound/sitehound-web/Input.html</ext-link>) [<xref rid="B52" ref-type="bibr">52</xref>] using default parameters. This server identifies ligand-binding sites by computing the interactions between a chemical probe and a protein structure.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Selection of the Highest Antigenic Protein</title><p>The query for Oropouche virus structural and nonstructural proteins resulted in a total of 208 hits in the ViPR database. All the structural proteins were evaluated by the VaxiJen v2.0 server, which predicted an overall score for each protein sequence and denoting the protein sequence as antigen or nonantigen. The protein sequence with the GenBank id ALB07207.1 exhibited the highest antigenic score 0.5124 among all the structural proteins. The protein itself is the OROV polyprotein containing 1420 amino acid residues, and this polyprotein was used for further analyses.</p></sec><sec id="sec3.2"><title>3.2. T-Cell Epitope Identification</title><p>The NetCTL 1.2 web server was used for the prediction of CD8<sup>+</sup> T-cell epitopes, and we considered the combined score for the epitope selection. In this study, we unraveled 128 epitopes in total, which achieved the selected threshold value 1.25 (<xref ref-type="supplementary-material" rid="supplementary-material-1">Table S1</xref>). The predicted T-cell epitopes were further evaluated by the VaxiJen server and the IEDB immunogenicity prediction tool. It has been repeated twice due to the loss of antigenicity property perceived in some T-cell epitopes. This repetition results facilitated to get a good rate of T-cell epitope prediction. Herein, among 128 primarily selected T-cell epitopes, 59 epitopes were under the threshold value 0.00 on the VaxiJen server, whereas 56 epitopes contained the immunogenicity value less than 0.00 (<xref ref-type="supplementary-material" rid="supplementary-material-1">Table S1</xref>). So, the results revealed that all epitopes with the highest combined score could not be the best epitopes. Among 128 epitopes, we selected 37 epitopes which have positive antigenicity and immunogenicity scores, so that these highly antigenic epitopes can interact to the MHC alleles with high affinity and can create an effective immune response (<xref ref-type="supplementary-material" rid="supplementary-material-1">Table S2</xref>). Finally, we identified 18 epitopes which contained more than &#x0003e;70% conservancy score, because the conservancy score is an important issue during the development of an effective vaccine. Epitope conservancy among the different strains of the selected protein can provide immunization effectively. So, the higher conservancy of an epitope ensures the better target for improved vaccine design. The selected epitopes, conservancy score, and their position are shown in <xref rid="tab1" ref-type="table">Table 1</xref>. In this study, 18 epitope conservancy analysis results revealed that the epitopes TSSWGCEEY, CSMCGLIHY, and LAIDTGCLY are 100.0% conserved, whereas the rest of the other 15 epitopes are conserved from 71.43% (RQHRGCIRF, YNVAWRTYL, and YLKNHNIDL) to 95.24% (CEEYGCLAI). However, among 18 T-cell epitopes, seven epitopes, including LIHYRPGLK, YLKNHNIDL, CEEYGCLAI, VPRYHSIDV, IPAISGLGV, AISGLGVGY, and RQHRGCIRF, have the VaxiJen score of more than 1 (&#x0003e;1) which indicates the high antigenicity nature of these epitopes (<xref rid="tab1" ref-type="table">Table 1</xref>). The immunogenicity score of the epitope can be a good criterion for the selection of the best epitope. The higher score designates a greater probability of eliciting an effective immune response. Herein, the epitopes RQHRGCIRF (0.18739), LEPIIGDKL (0.18454), and NLPHVVPRY (0.12889) are less immunogenic than the epitopes IFAAIIFAL (0.42861), SLIEICITL (0.3578), YNVAWRTYL (0.34779), IIFALIITK (0.32685), and TSSWGCEEY (0.29444), among 18 epitopes (<xref ref-type="supplementary-material" rid="supplementary-material-1">Table S2</xref>).</p><p>The selected 18 T-cell epitopes were found to be recognized by the significant MHC class-I molecule such as HLA-A, HLA-B, and HLA-C according to IEDB MHC class 1-binding analysis resource. We selected humans as MHC source species and the SMM method for the prediction of a distinct set of MHC HLA alleles for the humans. This tool gives an output result for HLA-binding affinity of the epitopes in the IC50&#x02009;nM unit. A lower IC50 value indicates higher binding affinity of the epitopes with the MHC class I molecule. So, in this study, we chose IC50 values less than 200&#x02009;nM (IC50 &#x0003c; 200) for ensuring higher affinity (<xref rid="tab1" ref-type="table">Table 1</xref>). For MHC-I processing, the analysis tool of the IEDB generates an overall score for each epitope's intrinsic potential of being a T-cell epitope based on proteasomal processing, TAP transport, and MHC-I-binding efficiency. Before being presented to the T-cells on the plasma membrane of the cell, the protein is degraded into small peptides in the proteasome by the cytosolic proteases and MHC-1 forms a complex with the peptides as well. Then, the MHC-I peptide complex is transported to the endoplasmic reticulum (ER) through heat shock proteins and transport-associated proteins (TAP). However, the higher the total score of the epitopes with the HLA alleles ensures the presentation to the T-cell and a successful immune response critically depends on it. The epitopes with their respective alleles and total scores are summarized in <xref rid="tab1" ref-type="table">Table 1</xref> and <xref ref-type="supplementary-material" rid="supplementary-material-1">Table S2</xref>. In this in silico analysis, the epitopes &#x0201c;CEEYGCLAI&#x0201d; and &#x0201c;RQHRGCIRF&#x0201d; were found as toxic to humans.</p><p>Effective immune response not only depends on the successful recognition of epitopes by HLA molecules with significant affinity but also depends on the antigenicity and immunogenicity score. So, the epitopes that were recognized by the considerable number of HLA alleles and contained the highest immunogenicity, antigenicity value, and nontoxic to human were considered as the potential epitope to induce a strong immune response. So, we selected two 100.0% conserved 9-mer epitopes &#x0201c;TSSWGCEEY&#x0201d; and &#x0201c;LAIDTGCLY&#x0201d; for docking purposes. Here, the epitope &#x0201c;TSSWGCEEY&#x0201d; showed the highest affinity for 11 MHC-1 molecules, including HLA-B<sup>&#x02217;</sup>27:20 (8.37), HLA-C<sup>&#x02217;</sup>03:03 (14.05), HLA-A<sup>&#x02217;</sup>32:07 (14.19), HLA-A<sup>&#x02217;</sup>68:23 (22.63), HLA-C<sup>&#x02217;</sup>12:03 (23.03), HLA-B<sup>&#x02217;</sup>40:13 (65.91), HLA-A<sup>&#x02217;</sup>32:15 (101.22), HLA-C<sup>&#x02217;</sup>07:01 (104.75), HLA-B<sup>&#x02217;</sup>15:02 (126.83), HLA-B<sup>&#x02217;</sup>15:17 (136.68), and HLA-B<sup>&#x02217;</sup>35:01 (180.13), whereas the epitope &#x0201c;LAIDTGCLY&#x0201d; exhibited the affinity with HLA-C<sup>&#x02217;</sup>03:03 (8.35), HLA-C<sup>&#x02217;</sup>12:03 (9.53), HLA-B<sup>&#x02217;</sup>15:17 (10.93), HLA-A<sup>&#x02217;</sup>68:23 (17.90), HLA-B<sup>&#x02217;</sup>35:01 (25.92), HLA-A<sup>&#x02217;</sup>32:07 (28.58), HLA-A<sup>&#x02217;</sup>29:02 (73.92), HLA-B<sup>&#x02217;</sup>15:01 (122.74), HLA-B<sup>&#x02217;</sup>15:03 (136.49), HLA-B<sup>&#x02217;</sup>15:02 (160.04), and HLA-B<sup>&#x02217;</sup>40:13 (169.80) (<xref rid="tab1" ref-type="table">Table 1</xref>). So, 7 MHC-I alleles HLA-C<sup>&#x02217;</sup>03:03, HLA-A<sup>&#x02217;</sup>32:07, HLA-C<sup>&#x02217;</sup>12:03, HLA-B<sup>&#x02217;</sup>40:13, HLA-B<sup>&#x02217;</sup>15:02, HLA-B<sup>&#x02217;</sup>15:17, and HLA-B<sup>&#x02217;</sup>35:01 were found as common in both &#x0201c;TSSWGCEEY&#x0201d; and &#x0201c;LAIDTGCLY.&#x0201d; However, we selected HLA-B<sup>&#x02217;</sup>35:01 for docking purposes due to the availability of this allele in the PDB database. After that, we further used the epitopes &#x0201c;TSSWGCEEY&#x0201d; and &#x0201c;LAIDTGCLY&#x0201d; for the prediction of MHC-II alleles and their respective peptide or CD4<sup>+</sup> T-cell epitope. The results showed that the epitope &#x0201c;TSSWGCEEY&#x0201d; and respective 15-mer peptides &#x0201c;KEHTSSWGCEEYGCL&#x0201d; and &#x0201c;EHTSSWGCEEYGCLA&#x0201d; have low affinity with the predicted MHC-II alleles (<xref rid="tab2" ref-type="table">Table 2</xref>). On the other hand, the epitope &#x0201c;LAIDTGCLY&#x0201d; was found as the core sequence of 31 15-mer peptides or CD4<sup>+</sup> T-cell epitopes in the range of the IC50 value 1&#x02013;3000&#x02009;nM. Among these 31 peptides, ten peptides exhibited a strong affinity (IC50 value 194 to 611&#x02009;nM) with HLA-DR alleles, HLA-DRB3<sup>&#x02217;</sup>01:01, HLA-DRB1<sup>&#x02217;</sup>03:01, and HLA-DRB1<sup>&#x02217;</sup>12:01 (<xref rid="tab2" ref-type="table">Table 2</xref>). So, HLA-DR alleles could be the best-binding grooves for the predicted peptides.</p></sec><sec id="sec3.3"><title>3.3. Analysis of Population Coverage and Allergenicity</title><p>MHC HLA allele distribution differs among diverse geographic regions and ethnic groups around the world. Therefore, population coverage must be taken into consideration during the design of an effective vaccine. In this study, for the population coverage, identified MHC-I-binding alleles of 18 epitopes were considered. A significant population coverage was found for the selected 18 epitopes in different geographic regions of the world (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="supplementary-material" rid="supplementary-material-1">Table S3</xref>). These epitopes and their HLA-alleles cover 96.44% of the world population. The highest population coverage was found in the European country Finland (99.69%) which was closely followed by Ireland, Germany, England, Poland, France, Italy, and Sweden with a population coverage of 99.51%, 99.19%, 98.66%, 98.60%, 98.40%, 97.27%, and 96.99%, respectively. The lowest population coverage was found in South Africa (1.53%). The Oropouche fever was first found in South America, especially in Brazil, and several outbreaks have been recorded in this country. So, the population coverage prediction in Brazil is essential for vaccine design. The cumulative population coverage in Brazil is 93.92%, but it is found as 95.77% in mixed Brazilian people (<xref ref-type="supplementary-material" rid="supplementary-material-1">Table S3</xref>). However, another South American country Chile has 92.79% population coverage. It varies in the North American country, especially in the United States people, and mostly covers the United States Caucasian race (98.96%) and United States African American (96.18%), United States Hispanic (95.86%), United States Mestizo (95.64%), United States Asian (94.58%), United States Polynesian (93.86%), and United States Amerindian (90.99%) people (<xref ref-type="supplementary-material" rid="supplementary-material-1">Table S3</xref>). The population coverage in West Africa is 91.97%, whereas the North African country Morocco and Sudan covers 96.69% and 96.64%, respectively, also followed by the East African country Zambia (97.75%) and Kenya (94.81%). However, the Oceanian country, Australia (Caucasian race), covers about 99.30% populations for the selected 18 epitopes and their respective alleles (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>Before vaccine design, the allergenicity prediction is a key step, because most vaccines transfer the immune response to the allergic reaction by initiating immunoglobulin E and Type II T-helper cells [<xref rid="B53" ref-type="bibr">53</xref>]. In that case, we predicted the allergenicity of the selected epitope through the AllergenFP 1.0 server. The server identified the epitopes, TSSWGCEEY, CSMCGLIHY, VPRYHSIDV, YNVAWRTYL, LEPIIGDKL, NSGPYNVAW, and AISGLGVGY as nonallergen and the rest of the other epitopes as a potential allergen to humans (<xref rid="tab1" ref-type="table">Table 1</xref>). On the contrary, AllerTOP v. 2.0 showed the allergenicity nature for the 100.0% conserved epitope TSSWGCEEY and 80.95% conserved epitope VPRYHSIDV. However, the results were found as the same for the rest of the other five epitopes (CSMCGLIHY, YNVAWRTYL, LEPIIGDKL, NSGPYNVAW, and AISGLGVGY) in both AllergenFP 1.0 and AllerTOP v. 2.0 servers (data not shown). The predicted three-dimensional structures of the T-cell epitopes were deposited to the Protein Model Database (PMDB). As a result, the database provided a unique accession number for each of the submissions of the epitope. The structure of the epitopes could be identified by using the accession number of PM0081248 and PM0081251 for T-cell epitopes TSSWGCEEY and LAIDTGCLY, respectively, in the PMDB database.</p></sec><sec id="sec3.4"><title>3.4. Docking Simulation Study</title><p>The molecular docking simulation study anticipated nine (9) potential binding affinities between the HLA-B<sup>&#x02217;</sup>35:01 and epitope TSSWGCEEY. At the same time, it was also found in the interaction between HLA-B<sup>&#x02217;</sup>35:01 and epitope LAIDTGCLY. The finest model was selected by higher binding affinity. The best interrelating model of epitope TSSWGCEEY and the HLA molecule contained a binding affinity of &#x02212;8.0&#x02009;kcal/mol. On the other hand, the epitope LAIDTGCLY and HLA molecule contained a binding affinity of &#x02212;8.4&#x02009;kcal/mol. The epitope position in the cartoon and surface structure and the binding interactions are shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>. The epitope and the HLA molecule interacted by the hydrogen bonds, and we found nine hydrogen bonds after the docking simulation between HLA-B<sup>&#x02217;</sup>35:01 and epitope TSSWGCEEY. In this study, the amino acid residues, namely, Tyr-7, Tyr-9, Tyr-99, Tyr-159, Trp-147, Thr-69, and Thr-73, acted as the hydrogen bond donors or acceptors with the epitope residues (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Herein, eight hydrogen bonds, 89 nonbonded contacts, and the interacting residues, Thr-143, Ser-77, Gln-155, Tyr-9, Asn-70, and Tyr-59, were found for HLA-B<sup>&#x02217;</sup>35:01 and epitope LAIDTGCLY.</p><p>The cartoon and surface structures were prepared and visualized by the PyMOL molecular graphics system.</p><p>In the control section, the docking between HLA-B<sup>&#x02217;</sup>35:01 and the influenza NP418 epitope (LPFERATVM) from the 2009 strain was performed. The best affinity or binding energy between these two molecules was found &#x02212;8.3&#x02009;kcal/mol, which is very close to the sample. The amino acid residues, namely, Tyr-7, Tyr-9, Tyr-99, Tyr-159, Tyr-171, Ser-77, and Gln-155, are involved in the interaction with the epitope residues (<xref ref-type="supplementary-material" rid="supplementary-material-1">Figure S1</xref>). So, the results revealed that Tyr-7, Tyr-9, Tyr-99, and Tyr-159 are conserved residues in the docking simulation of the sample (TSSWGCEEY) and control and ensuring the accuracy of the binding affinity. Besides, Tyr-9, Ser-77, and Gln-155 residues were found as common residues in the docking simulation of the sample LAIDTGCLY (binding affinity of &#x02212;8.4&#x02009;kcal/mol) and control which also ensures the accuracy and the acceptance of the docking simulation.</p><p>The epitope (peptide) binding to the MHC class II HLA-DR molecule is important for the proper functioning of a vaccine candidate. So, we predicted the alleles for our selected epitope and performed a docking study between those molecules. Herein, we found the best binding affinity &#x02212;7.9&#x02009;kcal/mol for the docking study among the predicted nine binding affinity results. This result indicates a good affinity between HLA-DR and the epitope LAIDTGCLY (<xref ref-type="fig" rid="fig4">Figure 4</xref>). During the analysis of the interaction between HLA-DR and LAIDTGCLY, we found five hydrogen bonds and 125 nonbonded contacts in the combined structure. However, the amino acid residues, namely, Ser-53, Gln-9, Asn-62 (2 times), and His-13, are involved in the interaction with the epitope residues (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p></sec><sec id="sec3.5"><title>3.5. Analysis of Linear and Conformational B-Cell Epitopes</title><p>A B-cell epitope is a precise portion of an antigen recognized by either a specific B-cell receptor or the elicited antibody in a humoral response [<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B54" ref-type="bibr">54</xref>]. The B-cell epitopes are divided into two main categories such as continuous or linear B-cell epitope and discontinuous or conformational B-cell epitope. It has been found that most of the B-cell epitopes are conformational epitopes, and the amount of this epitope is more than 90% [<xref rid="B55" ref-type="bibr">55</xref>].</p><p>The prediction of B-cell epitopes from the antigenic protein is the major step of epitope-based vaccine design. Thus, to get essential B-cell epitope candidates in the polyprotein of OROV, we performed an in silico analysis through the web server BepiPred-2.0 and LBtope.</p><p>Based on the BepiPred-2.0 method, a total of 31 linear B-cell epitopes with varied length were identified from the polyprotein of OROV. Among all these predicted epitopes, 8 B-cell epitopes <sup>81</sup>VKDWSECNPVLDKL<sup>94</sup>, <sup>334</sup>AGERMYKLEELADD<sup>347</sup>, <sup>504</sup>YIMGDTCVSKSELYSDLLSKNLITEYDKKYFEPDTVN<sup>540</sup>, <sup>875</sup>CSEQRFPIHKNWFKKCNWDKTHKEFTTMRQINYNDITSYRKAIES<sup>919</sup>, <sup>922</sup>GTDLMTHHYKPTKNLPHVVPRYH<sup>944</sup>, <sup>1095</sup>ETYCNDMDILEPIIGD<sup>1110</sup>, <sup>1186</sup>FNDNYQSCT<sup>1194</sup>, and <sup>1231</sup>DINYKIFTKSV<sup>1241</sup> were nonantigenic as predicted by the VaxiJen v2.0 server. These epitopes had 5.56% to 55.56% conservancy level, except FNDNYQSCT (100% conservancy score), among the specified polyprotein sequences (<xref rid="tab3" ref-type="table">Table 3</xref>). So, these epitopes could not be the vaccine candidates. On the other hand, the epitopes <sup>17</sup>HPLSTSQIGDRC<sup>28</sup> (94.44%), <sup>35</sup>FKEMNLSVGL<sup>44</sup> (100%), <sup>282</sup>SCTEALKVHRMGKDCLGYKS<sup>301</sup> (100%), <sup>566</sup>ECEMLSLKKNSGPYN<sup>580</sup> (100%), <sup>594</sup>LCSRHNY<sup>600</sup> (100%), <sup>1026</sup>PEKIPAKEGWLTFSKEHTSSW<sup>1046</sup> (100%), and <sup>1119</sup>TQTNQLP<sup>1125</sup> (100%) can be considered as vaccine candidates due to their antigenicity and high conservancy score (<xref rid="tab3" ref-type="table">Table 3</xref>). After the prediction of allergenicity (AllerTOP 2.0 and AllergenFP v. 1.0) and toxicity, it can be said that the epitopes <sup>17</sup>HPLSTSQIGDRC<sup>28</sup>, <sup>1026</sup>PEKIPAKEGWLTFSKEHTSSW<sup>1046</sup>, and <sup>788</sup>SHCNLEFTAITADKIMSL<sup>805</sup> could be the potential linear B-cell epitopes for vaccine design (<xref rid="tab3" ref-type="table">Table 3</xref>).</p><p>During the prediction by LBtope, a total of 19 linear B-cell epitopes were found from the OROV polyprotein. The epitopes <sup>13</sup>IAYGHPLSTSQI<sup>24</sup>, <sup>110</sup>PRMYTCRAACDI<sup>121</sup>, <sup>432</sup>SSGFEYEVFLKDMH<sup>445</sup>, <sup>519</sup>DLLSKNLITEYDKKYFEPDTVNDQFNKIEFAQD<sup>551</sup>, <sup>619</sup>DFNNEIETYYKANAAAYRSDFYTI<sup>642</sup>, <sup>706</sup>TRSAQHSIMTN<sup>716</sup>, <sup>848</sup>CGDKYYYSDGKEHAKDGS<sup>865</sup>, and <sup>1089</sup>CITLPHETYCNDMDILEPII<sup>1108</sup> are nonantigenic among the 19 epitopes due to their low antigenicity score in the VaxiJen server (<xref rid="tab4" ref-type="table">Table 4</xref>). On the contrary, the epitopes <sup>889</sup>KCNWDKT<sup>895</sup>, <sup>928</sup>HHYKPTKNLPHVVPRYH<sup>944</sup>, <sup>1273</sup>CHCKTNCED<sup>1281</sup>, and <sup>1327</sup>NQKIDLSQL<sup>1335</sup> were found as antigenic and 100% conserved among all the predicted epitopes. However, the epitopes <sup>889</sup>KCNWDKT<sup>895</sup> and <sup>1273</sup>CHCKTNCED<sup>1281</sup> could not be the potential vaccine candidates because these two B-cell epitopes were identified as toxic to the human (<xref rid="tab4" ref-type="table">Table 4</xref>).</p><p>After the similarity search between BepiPred-2.0 and LBtope predicted B-cell epitopes, we identified 18 sequences as most conserved B-cell epitopes. However, 7 B-cell epitopes were found as nonantigenic and less conserved (5.56% to 38.89%), except the epitopes <sup>1095</sup>ETYCNDMDILEPII<sup>1108</sup> (100%) and <sup>1188</sup>DNYQSCT<sup>1194</sup> (100%) (<xref rid="tab5" ref-type="table">Table 5</xref>). The predicted epitope <sup>928</sup>HHYKPTKNLPHVVPRYH<sup>944</sup> is 100% conserved, which is also followed by <sup>1327</sup>NQKIDLSQL<sup>1335</sup> (100%), <sup>889</sup>KCNWDKT<sup>895</sup> (100%), and <sup>17</sup>HPLSTSQI<sup>24</sup> (94.44%). The analysis of antigenicity, conservancy, toxicity, and allergenicity of B-cell epitopes revealed that the epitope <sup>928</sup>HHYKPTKNLPHVVPRYH<sup>944</sup>could be the most potential B-cell epitope candidate for peptide-based vaccine design because this epitope is antigenic, 100% conserved, nontoxic, and nonallergenic to the human. The exact position and length of the predicted B-cell epitopes are shown in <xref rid="tab5" ref-type="table">Table 5</xref>.</p><p>In this study, a total of 8 discontinuous or conformational B-cell epitopes were predicted using the ElliPro tool of IEDB. The epitopes having a protrusion index (PI) score above 0.8 were taken into consideration. The PI value of the 8 predicted epitopes ranged from 0.837 to 0.906. The residues with higher scores indicate better solvent accessibility. Herein, the highest probability of a discontinuous epitope was calculated at 90.6% (PI score: 0.906) and is shown in <xref ref-type="fig" rid="fig5">Figure 5(a)</xref>. Conformational epitopes and their individual residues, residue position, length, and the scores are shown in <xref rid="tab6" ref-type="table">Table 6</xref>, whereas the positions of epitopes on 3D structures are exhibited in Figures <xref ref-type="fig" rid="fig5">5(a)</xref>&#x02013;<xref ref-type="fig" rid="fig5">5(h)</xref>.</p></sec><sec id="sec3.6"><title>3.6. Ligand-Binding Pocket Analysis</title><p>The physicochemical properties of the OROV polyprotein were found as 8.01 isoelectric points, 37.22 instability index value, 88.99 aliphatic index values, and &#x02212;0.138 GRAVY value. The other features are shown in <xref rid="tab7" ref-type="table">Table 7</xref>. These results revealed that the protein is naturally mildly basic, stable, and hydrophilic. The secondary structural features showed that the random coils with 45.99% is dominated by alpha helix (31.62%) and extended strands (22.39%) (<xref ref-type="supplementary-material" rid="supplementary-material-1">Figure S2</xref>). The unstructured or disordered regions can play an important role in the catalytic activity of the protein that was predicted by the DISOPRED3 server. The disordered regions were found in the <sup>528</sup>EY<sup>529</sup>, <sup>535</sup>E, <sup>705</sup>STRSAQHS<sup>712</sup>, <sup>723</sup>PF<sup>724</sup>, and <sup>727</sup>YS<sup>728</sup> positions. The disordered regions and their confidence score are shown in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p><p>The 3D structure of the OROV polyprotein is not available in the PDB database. So, a 3D structure of the OROV polyprotein was predicted by the I-TASSER server and visualized by the PyMOL tools (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Different evaluation scores of the I-TASSER server, such as C-score (&#x02212;1.02), estimated TM score (0.59&#x02009;&#x000b1;&#x02009;0.14), estimated RMSD (12.3&#x02009;&#x000b1;&#x02009;4.4&#x02009;&#x000c5;), cluster density (0.1329), and number of decoys (213), ensured the good quality of the predicted model. Energy minimization through the ModRefiner server and Swiss-PdbViewer software tools removes the bad contacts of the predicted protein model. The total force field energy of the protein structure was &#x02212;36896.734&#x02009;kJ/mol after energy minimization. Here, PROCHECK was used to check the stereochemical quality of the structure by considering residue geometry and overall structural geometry. The results showed 72.2% in most favored regions, 21.9% in the additional allowed region, 3.6% in the generously allowed region, and 2.3% in the disallowed region in the Ramachandran plot statistics (<xref ref-type="supplementary-material" rid="supplementary-material-1">Figure S3</xref>). To check the potential errors of the protein 3D model, ProSA was used, and it predicts the negative <italic>Z</italic>-score of &#x02212;6.67, which ensures the good quality of the model (<xref ref-type="supplementary-material" rid="supplementary-material-1">Figure S4</xref>). The ProQ server showed an LG score of 3.651 (LG score &#x0003e; 2.5 indicates very good model) and MaxSub score of 0.500 (MaxSub &#x0003e; 0.5 indicates very good model), ensuring the &#x0201c;very good&#x0201d; quality of the predicted protein model. Another evaluation tool QMEAN gave different scores with an environmental profile graph for the OROV polyprotein structure (<xref ref-type="supplementary-material" rid="supplementary-material-1">Figure S5</xref>). The refined and evaluated protein model was submitted to the PMDB database, and the server provided a unique accession id PM0081042 for the submitted model. The hydrophobicity nature greatly impacts the drug design and delivery system. The hydrophobicity plot of the OROV polyprotein is shown in <xref ref-type="supplementary-material" rid="supplementary-material-1">Figure S6</xref>.</p><p>The ligand-binding pockets of OROV polyprotein were not reported yet. So, the SiteHound server was used to predict the top 10 ligand-binding pockets of the OROV polyprotein which ranked by energy (<xref rid="tab8" ref-type="table">Table 8</xref>). The surface volume of the binding pockets was also explored in the center <italic>x</italic>-axis, <italic>y</italic>-axis, and <italic>z</italic>-axis. The residues which are involved in the formation of protein cavities were explored for copious binding of new ligands such as epitope. The energy was ranged from &#x02212;1677.27 to &#x02212;940.23 which ensures the efficiency of the predicted top 10 ligand-binding pockets. These ligand-binding pockets could be the target for molecular docking simulation in the future.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>In recent years, many diseases have emerged due to the occurrence of several outbreaks through the different types of newer viruses. So, vaccine development against these emerging diseases within a short time is very crucial to protecting the people from the rising viral attacks. Vaccines are the pharmacological products which can provide the finest cost-benefit ratio in the prevention or treatment of diseases. However, an effective vaccine progression and production are costly and can take years to be completed. So, the researchers have tried for many years to minimize the cost and time for the development of vaccines. At this time, there are different strategies available for the design and development of effective and safe new-generation vaccines based on the Bioinformatics approaches [<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>]. The next-generation sequencing and progressive genomics and proteomics technologies have brought about a great change in computational immunology. However, the advancement of newer immunoinformatics tools has made a broader way in developing the vaccine or vaccine candidates through the satisfactory understanding of the immune response of the human body against an organism within a short time [<xref rid="B58" ref-type="bibr">58</xref>&#x02013;<xref rid="B60" ref-type="bibr">60</xref>].</p><p>After recovery from an acute viral or microbial infection, a person generally achieves long-term or even lifelong immunity to the same viral disease or pathogen [<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>]. Numerous acute viral infections exhort a protective humoral response which is characterized by the presence of a preexisting antibody. However, the duration of this preexisting antibody response differs among viral infections and can exist for a few months to many years in the host [<xref rid="B63" ref-type="bibr">63</xref>]. Slifka and Ahmed reported that the antibody persistence of acute viral infection in humans, such as Chikungunya, Rift Valley fever virus, dengue, yellow fever, and measles, are about 30 years, 12 years, 32 years, 75 years, and 65 years, respectively [<xref rid="B63" ref-type="bibr">63</xref>]. According to Tesh and Vasconcelos, OROV could not be isolated from the patient's serum during the recurrent illness, but the detectable humoral antibodies are usually found [<xref rid="B64" ref-type="bibr">64</xref>]. However, no significant fatalities have been stated for OROV, and the lifelong immunity ensures the recovery from this emerging virus [<xref rid="B64" ref-type="bibr">64</xref>].</p><p>B-cell memory consists of humoral memory (long-lived antibody-secreting plasma cells) and reactive memory (long-lived memory B-cells which can react quickly to a recurrent antigenic challenge) [<xref rid="B61" ref-type="bibr">61</xref>]. Mainly memory B-cells afford the potential to respond fast and with more adapted antibodies against reinfection [<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B65" ref-type="bibr">65</xref>]. Welsh et al. concluded that memory B-cell responses are long-lived even in the absence of antigen, but these responses are controlled and influenced by other infections in the host. This memory B-cells are responsible for providing long-term protective immunity or contribute to immunopathology on infection with homologous or heterologous viruses [<xref rid="B66" ref-type="bibr">66</xref>]. B-cell memory is virus-specific, but the exact cellular mechanisms of virus-specific antibody response to acute viral infection remain unclear [<xref rid="B67" ref-type="bibr">67</xref>]. Hebeis et al. demonstrated that the activation of virus-specific memory B-cells to secrete immunoglobulin G (Ig G) is autonomous of cognate or bystander T-cell help [<xref rid="B68" ref-type="bibr">68</xref>]. The role of virus-specific B-cell memory has been found in mumps virus [<xref rid="B69" ref-type="bibr">69</xref>], human influenza virus [<xref rid="B70" ref-type="bibr">70</xref>], rotavirus [<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>], and dengue virus [<xref rid="B73" ref-type="bibr">73</xref>].</p><p>In recent trends, the surface glycoprotein (GP) is considered as the initial focus for the development of epitope-based peptide vaccine, as they are involved in the interaction between cell receptor and virus particle, thus playing a significant role in the pathogenesis of the disease [<xref rid="B74" ref-type="bibr">74</xref>]. To our knowledge, the subunit or epitope/peptide-based vaccine approaches have not been used yet for the prediction of a potential vaccine against this neglected emerging OROV. However, the virus-like particle assay has been developed for this OROV that could be used as a tool to develop a potential recombinant vaccine [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B74" ref-type="bibr">74</xref>]. The population coverage information of the epitopes and their respective HLA alleles are crucial to being the potential vaccine candidates. The computational prediction of this HLA allele is much easier and cost-effective than the experimental one. Therefore, in this study, different types of immunoinformatics and molecular simulation tools were used to find the potential vaccine candidates present in the OROV polyprotein.</p><p>In the present study, an immunoinformatics-driven approach was incorporated to screen emergent immunogen against OROV proteome. The results revealed that the OROV polyprotein was the most antigenic protein with the highest antigenic scores (0.5124) compared with other viral proteins of OROV. To our knowledge, no immunoinformatics study for the OROV polyprotein has been performed yet for the identification of a potential vaccine target. Although we found the polyprotein as a potential antigenic protein, another OROV protein may be the source of vaccine candidate identification. However, we identified the potential T-cell epitopes from the most antigenic polyprotein, as they play a key role in the creation of a defensive immune response against different pathogenic infections [<xref rid="B75" ref-type="bibr">75</xref>]. Various successful studies have been performed for the epitope-based peptide vaccine design against West Nile virus [<xref rid="B76" ref-type="bibr">76</xref>], Zika virus [<xref rid="B77" ref-type="bibr">77</xref>], dengue virus [<xref rid="B78" ref-type="bibr">78</xref>], Chikungunya virus [<xref rid="B79" ref-type="bibr">79</xref>], Rift valley fever virus [<xref rid="B80" ref-type="bibr">80</xref>], shigellosis [<xref rid="B81" ref-type="bibr">81</xref>], and so on. Primarily, we identified 146 epitopes in total using 12 supertypes (A1, A2, A3, A24, A26, B7, B8, B27, B39, B44, B58, and B62) and selected 128 epitopes based on the highest combined score. Finally, we identified 18 epitopes by maintaining some critical criteria such as antigenicity, immunogenicity, and most important conservancy scores of the epitopes (<xref rid="tab1" ref-type="table">Table 1</xref>). We gave priority to the higher conservancy score of the epitopes because higher conservancy ensures the extensive protection across numerous strains or even species. Our selected 18 T-cell epitopes were 70.0% to 100.0% conserved which could ensure the acceptance of these predicted epitopes and indicate them as a potential vaccine candidate. Hossain et al. showed 65.66% conserved epitope &#x0201c;TLKNLNDNY&#x0201d; as a potential vaccine candidate for universal vaccine design against rotavirus [<xref rid="B82" ref-type="bibr">82</xref>]. On the contrary, Hasan et al. revealed 69.49% conserved epitope &#x0201c;YYYELYPTM&#x0201d; as a possible vaccine lead for vaccine design against Chikungunya virus [<xref rid="B79" ref-type="bibr">79</xref>]. Since our predicted 18 epitopes are highly conserved (3 epitopes&#x02014;100% conserved, 1 epitope&#x02014;95.24% conserved, 8 epitopes&#x02014;80.95% conserved, 3 epitopes&#x02014;76.19% conserved, and 3 epitopes&#x02014;71.43% conserved), these epitopes could be considered as potential vaccine candidates for vaccine design against OROV. Predicted 100.0% conserved epitopes TSSWGCEEY, CSMCGLIHY, and LAIDTGCLY were found as antigenic, but the antigenicity was lower than the epitopes, CEEYGCLAI (95.24%), LIHYRPGLK (80.95%), VPRYHSIDV (80.95%), IPAISGLGV (76.19%), and YLKNHNIDL (71.43%). However, the epitope CSMCGLIHY could be the most important epitope in comparison with the rest of the other epitopes, because it is not allergenic (as predicted by both AllergenFP 1.0 and AllerTOP v. 2.0 servers) and nontoxic to the host. At present, the researchers are using different immunoinformatics approaches for the prediction of high potential CD4<sup>+</sup> T-cell epitopes and CD8<sup>+</sup> T-cell epitopes which can bind to different MHC-I and MHC-II molecules. de Freitas e Silva et al. identified 10 top-ranked epitopes from the proteome of <italic>Leishmania braziliensis</italic> using immunoinformatics tools and also synthesized and assessed in vitro to stimulate peripheral blood mononuclear cells (PBMC) from posttreated cutaneous leishmaniasis patients and found that 50% of these epitopes are immunogenic [<xref rid="B83" ref-type="bibr">83</xref>]. Khan et al. identified the T-cell epitopes from the <italic>Mycobacterium tuberculosis</italic> proteome using the in silico approaches for in vitro analyses and found T-cell responses during experimental evaluation of the identified epitopes [<xref rid="B84" ref-type="bibr">84</xref>]. So, the analysis clearly revealed that the immunoinformatics or <italic>in silico</italic> approaches could make a great contribution in vaccine lead identification for experimental study and/or the design of an effective vaccine.</p><p>The HLA alleles maintain the response to T-cell epitopes, and these alleles are extremely polymorphic in numerous ethnic populations. Therefore, MHC-I and MHC-II HLA allele specificity of T-cell epitopes should be considered as the initial criteria to induce extensive immune responses in diverse ethnic human populations [<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>]. However, to get more population coverage, the T-cell epitope should bind with more MHC HLA alleles. So, we took the selected 18 epitopes and their respective MHC-I-binding HLA alleles for significant population coverage. The results revealed that the selected epitopes and their alleles have ideal population coverage in different geographic regions around the world. The highest population coverage was recorded at 99.69% in Finland, and those epitopes and their respective HLA-alleles cover 96.44% of the world population. The OROV outbreak occurred in the South American countries, especially in Brazil in the highest proportions. So, the vaccine candidates for this geographic region are essential to protecting individuals from OROV infection. The population coverage was found at 95.77% among the mixed Brazilian population, which indicates the acceptability of the epitopes for the OROV epidemic region. It was observed that the population coverage (1.53%) was found lower than the other countries (<xref ref-type="fig" rid="fig2">Figure 2</xref>). South Africa consists of different ethnic groups, but the HLA distribution in the allele frequency net database (AFND) is comparatively low which reflects the underrepresentation of this region. Tshabalala et al. reviewed that HLA-C alleles are mostly found in Caucasian South Africans, Black South Africans, Shona Zimbabweans, Tamil South Africans, and Zambians while HLA-B allele frequencies are found in Shonas and Black South Africans [<xref rid="B87" ref-type="bibr">87</xref>]. Cao et al. reported 9 different HLA alleles, HLA-A<sup>&#x02217;</sup> 02:02, HLA-B<sup>&#x02217;</sup>15:03, HLA-A<sup>&#x02217;</sup>34:02, HLA-A<sup>&#x02217;</sup>36:01, HLA-B<sup>&#x02217;</sup>42:01, HLA-B<sup>&#x02217;</sup>53:01, HLA-B<sup>&#x02217;</sup>57:03, HLA-B<sup>&#x02217;</sup>58:02, and HLA-A<sup>&#x02217;</sup>74:01, as unique African alleles [<xref rid="B88" ref-type="bibr">88</xref>]. On the other hand, a very low amount of HLA class-II alleles is available in South African populations. Among all HLA class-II alleles, HLA-DRB1 alleles are available in most South Africans, while HLA-DP data were found in only Zimbabwean Shonas and Black South Africans, but no alleles were reported for DQA1 in AFND [<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B89" ref-type="bibr">89</xref>]. So, the unavailability of our predicted HLA-alleles in the South African population could be the main cause of the lowest population coverage in South Africa. The 3D structure of the epitopes TSSWGCEEY and LAIDTGCLY were designed for docking purposes and compared with a control (HLA-B<sup>&#x02217;</sup>35:01 and influenza NP418 epitope) to measure the docking efficiency with a specific HLA allele HLA-B<sup>&#x02217;</sup>35:01. The docking results showed almost similar binding affinity or energy for both the control (&#x02212;8.3&#x02009;kcal/mol) and the sample (&#x02212;8.4&#x02009;kcal/mol and &#x02212;8.0&#x02009;kcal/mol for the epitopes &#x0201c;LAIDTGCLY&#x0201d; and &#x0201c;TSSWGCEEY,&#x0201d; respectively) which designates the satisfactory accuracy of the predicted epitopes to form an interaction with the MHC-I allele. However, another docking was performed between the MHC-II allele and the selected epitope &#x0201c;LAIDTGCLY&#x0201d; which also exhibits the satisfactory binding affinity. So, the results indicate the epitope &#x0201c;LAIDTGCLY&#x0201d; as a novel vaccine candidate of OROV.</p><p>In this study, five linear B-cell epitopes <sup>17</sup>HPLSTSQIGDRC<sup>28</sup> (94.44%), <sup>788</sup>SHCNLEFTAITADKIMSL<sup>805</sup> (83.33%), <sup>928</sup>HHYKPTKNLPHVVPRYH<sup>944</sup> (100%), <sup>1026</sup>PEKIPAKEGWLTFSKEHTSSW<sup>1046</sup> (100%), and <sup>1327</sup>NQKIDLSQL<sup>1335</sup> (100%) showed the highest conservancy among diverse OROV isolates compared with other epitopes, proposing that these epitopes might be the ideal vaccine candidates based on the fact that an epitope should be as conservative as possible to provide extensive protection among different virus isolates. These epitopes were also identified as nontoxic to humans. However, the cross processing of the BepiPred-2.0 and LBtope predicted B-cell epitope data revealed that the 17-mer epitope <sup>928</sup>HHYKPTKNLPHVVPRYH<sup>944</sup> is the most potent B-cell epitope. Besides, the discontinuous B-cell epitopes were drawn on the polyprotein of OROV (<xref ref-type="fig" rid="fig5">Figure 5</xref>). All the predicted discontinuous or conformational epitopes were placed on the surface of the OROV polyprotein, representing the accessibility for the entered virus.</p><p>As recommended by the antigenicity analysis through the VaxiJen server, the polyprotein of OROV seemed to be a suitable vaccine target. The important information was found from the physicochemical properties and secondary structural features of the protein by the ExPASy ProtParam and PSIPRED servers. The protein was found to be basic, stable, and hydrophilic in nature and could sustain high temperature due to a higher aliphatic index value. The abundance of random coils in the OROV polyprotein structure ensured the higher conservancy and stability of the protein [<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B90" ref-type="bibr">90</xref>]. This protein contained disordered regions in some specific positions. The most disordered region was positioned in the 705 to 712 (STRSAQHS) location in the protein. The predicted 3D structure of the OROV polyprotein by the I-TASSER server was acceptable. The energy minimization and evaluation results ensured the good quality of the predicted model. The evaluated model was submitted to the PMDB database for further research in the future. To support the future drug discovery and drug design, ligand-binding pockets and hydrophobicity analyses were accomplished. However, ten possible ligand-binding pockets and their respective amino acid residues were found. The results suggested that the binding residues of these pockets could be the future research prospect for effective inhibitor design against emerging OROV infection.</p><p>Peptide's half-life prediction is one of the key challenges in successful peptide vaccine design as its bioavailability depended on the extent of the half-life. So it is vital to identify the optimal half-life of the peptide for ensuring their optimal function [<xref rid="B91" ref-type="bibr">91</xref>] post-vaccination. Recently, a database called &#x0201c;PEPlife&#x0201d; has been developed as a repository of the half-life of peptides [<xref rid="B92" ref-type="bibr">92</xref>]; however, it is customary to test and measure for the peptide half-life to ensure optimal protection post-vaccination. Cytokines play an important role in elucidating humoral immune response against antiviral activity, and methods have been developed to predict the different interleukins such as IFN-<italic>&#x003b3;</italic> [<xref rid="B93" ref-type="bibr">93</xref>], IL-4 [<xref rid="B94" ref-type="bibr">94</xref>], and IL-10 [<xref rid="B95" ref-type="bibr">95</xref>]. In general, protein-based vaccines have limited immunogenicity and reactogenicity compared to live-attenuated and inactivated vaccines, although protein-based vaccines have greater advantages in relation to safety and cost-effectiveness [<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B97" ref-type="bibr">97</xref>]. An overarching strategy to achieve maximum protection against viral infections is to design a successful peptide-based vaccine following the identification of crucial epitopes via the immunoinformatic approach combined with effective adjuvant choice. Adjuvants are substances added to vaccine formulations that influence the onset, strength, and longevity of specific immune responses to antigens and induce protection against infection [<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B98" ref-type="bibr">98</xref>]. Moreover, adjuvants receive much attention due to their ability to selectively modulate the immune response to elicit humoral and/or cell-mediated immune response [<xref rid="B97" ref-type="bibr">97</xref>]. A number of approved vaccine adjuvants such as aluminium salts, oil-in-water (o/w) emulsions, virosomes, liposomes, monophosphoryl lipid A, and TLR agonist are available, but at this time in silico adjuvant prediction tools are not available due to the unavailability of sufficient data and exact molecular mechanism of vaccine adjuvants.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>This study provided valuable insights for the identification of vaccine candidates and ligand-binding pockets against the neglected and emerging OROV infection through the immunoinformatics as well as Bioinformatics approaches. Based on this strategy, the T-cell and B-cell epitopes in the polyprotein of OROV were mapped and selected as putative OROV vaccine targets. The predicted epitopes exhibited T-cell and B-cell selectivity, higher conservancy, nonallergenicity, nontoxicity, higher population coverage, and significant interaction with MHC class I allele with good affinity. Nonetheless, these findings will provide primary data for molecular docking and epitope-based peptide vaccine research in the future.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are thankful to Professor A.K.M Akhtarul Islam, Department of English, Islamic University, Kushtia, for editing and checking the spelling and grammatical error of this manuscript.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>OROV:</term><def><p>Oropouche virus</p></def></def-item><def-item><term>CNS:</term><def><p>Central nervous system</p></def></def-item><def-item><term>CTL:</term><def><p>Cytotoxic T-lymphocytes</p></def></def-item><def-item><term>FAO:</term><def><p>Food and Agriculture Organization</p></def></def-item><def-item><term>GRAVY:</term><def><p>Grand average hydropathicity</p></def></def-item><def-item><term>HMM:</term><def><p>Hidden Markov model</p></def></def-item><def-item><term>IRF-3:</term><def><p>Interferon regulatory transcription factor</p></def></def-item><def-item><term>MAVS:</term><def><p>Mitochondrial antiviral signaling protein</p></def></def-item><def-item><term>MHC-I:</term><def><p>Major histocompatibility complex class I</p></def></def-item><def-item><term>MHC-II:</term><def><p>Major histocompatibility complex class II</p></def></def-item><def-item><term>PI:</term><def><p>Protrusion index</p></def></def-item><def-item><term>PMDB:</term><def><p>Protein model database</p></def></def-item><def-item><term>PDB:</term><def><p>Protein Data Bank</p></def></def-item><def-item><term>SMM:</term><def><p>Stabilized matrix base method</p></def></def-item><def-item><term>SVM:</term><def><p>Support vector machine</p></def></def-item><def-item><term>TAP:</term><def><p>Transport-associated protein</p></def></def-item><def-item><term>WHO:</term><def><p>World Health Organization.</p></def></def-item></def-list></glossary><sec sec-type="data-availability"><title>Data Availability</title><p>The data used to support the findings of this study are available from the corresponding author upon request.</p></sec><sec><title>Conflicts of Interest</title><p>The authors declare that they have no competing interests.</p></sec><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supplementary Materials</title><supplementary-material content-type="local-data" id="supp-1"><label>Supplementary 1</label><caption><p>Figure S1: docking simulation study (control). (A) The docking results as the surface structure of the MHC-I HLA allele &#x0201c;HLA-B<sup>&#x02217;</sup>35:01&#x0201d; (cyan color) and the sticky form of epitope &#x0201c;LPFERATVM&#x0201d; (red color). The black color box represents the position of epitope in the surface structure. (B) Epitope in the cartoon structure. (C) Sticky form of epitope &#x0201c;LPFERATVM&#x0201d; (red color) with residue position. (D) Binding interaction of the epitope residues and the HLA-B<sup>&#x02217;</sup>35:01 residues through the hydrogen bonds. Hydrogen bonds and the distances are shown in green color.</p></caption><media xlink:href="6718083.f1.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-2"><label>Supplementary 2</label><caption><p>Figure S2: secondary structure of the OROV polyprotein, ALB07207.</p></caption><media xlink:href="6718083.f2.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-3"><label>Supplementary 3</label><caption><p>Figure S3: Ramachandran plot analysis of OROV polyprotein. Here, the red region indicates the favored region, the yellow region for the allowed region, light yellow for the generously allowed region, and white for the disallowed region. Phi and Psi angles determine torsion angles.</p></caption><media xlink:href="6718083.f3.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-4"><label>Supplementary 4</label><caption><p>Figure S4: ProSA&#x02014;web results of the OROV polyprotein. (A) ProSA&#x02014;web <italic>z</italic>-scores of all protein chains in PDB determined by X-ray crystallography (light blue) or NMR spectroscopy (dark blue) with respect to their length. The <italic>z</italic>-score of the OROV polyprotein is highlighted as large dots. (B) Energy plot of the OROV polyprotein. Residue energies averaged over a sliding window are plotted as a function of the central residue in the window. (C) Jmol C<italic><sup>&#x003b1;</sup></italic> trace of the OROV polyprotein. Residues are colored from blue to red in the order of increasing residue energy.</p></caption><media xlink:href="6718083.f4.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-5"><label>Supplementary 5</label><caption><p>Figure S5: QMEAN score and QMEANDisCo score of the OROV polyprotein. (A) QMEAN4 score with linear combination of four statistical potential terms. (B) QMEAN6 score with two additional agreement terms evaluating the consistency of structural features with sequence-based predictions. (C) Predicted local similarity to target structure. (D) QMEANDisCo scoring plot. It compares local QMEAN scores with local DisCo scores and the resulting QMEANDisCo scores. Depending on the situation of finding homologous, DisCo is not necessarily defined everywhere.</p></caption><media xlink:href="6718083.f5.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-6"><label>Supplementary 6</label><caption><p>Figure S6: hydrophobicity plot analysis of OROV polyprotein, ALB07207.</p></caption><media xlink:href="6718083.f6.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-7"><label>Supplementary 7</label><caption><p>Table S1: total 128 epitopes predicted for 12 super types. (&#x0221a;) indicating the acceptance of the epitope which has both positive antigenicity and immunogenicity scores.</p></caption><media xlink:href="6718083.f7.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-8"><label>Supplementary 8</label><caption><p>Table S2: 37 CD8<sup>+</sup> T-cell epitopes and their combined score, antigenicity, immunogenicity, conservancy, and MHC-I interaction.</p></caption><media xlink:href="6718083.f8.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-9"><label>Supplementary 9</label><caption><p>Table S3: population coverage for the selected 18 epitopes and their HLA alleles.</p></caption><media xlink:href="6718083.f9.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasconcelos</surname><given-names>H. B.</given-names></name><name><surname>Nunes</surname><given-names>M. R. T.</given-names></name><name><surname>Casseb</surname><given-names>L. M. N.</given-names></name><etal/></person-group><article-title>Molecular epidemiology of Oropouche virus, Brazil</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2011</year><volume>17</volume><issue>5</issue><fpage>800</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.3201/eid1705.101333</pub-id><pub-id pub-id-type="other">2-s2.0-79955773973</pub-id><?supplied-pmid 21529387?><pub-id pub-id-type="pmid">21529387</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Rosa</surname><given-names>J. F. T.</given-names></name><name><surname>de Souza</surname><given-names>W. M.</given-names></name><name><surname>de Paula Pinheiro</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Oropouche virus: clinical, epidemiological, and molecular aspects of a neglected Orthobunyavirus</article-title><source><italic toggle="yes">The American Journal of Tropical Medicine and Hygiene</italic></source><year>2017</year><volume>96</volume><issue>5</issue><fpage>1019</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.16-0672</pub-id><pub-id pub-id-type="other">2-s2.0-85017116126</pub-id><?supplied-pmid 28167595?><pub-id pub-id-type="pmid">28167595</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinheiro</surname><given-names>F. P.</given-names></name><name><surname>Travassos da Rosa</surname><given-names>A. P. A.</given-names></name><name><surname>Travassos da Rosa</surname><given-names>J. F. S.</given-names></name><etal/></person-group><article-title>Oropouche virus. I. A review of clinical, epidemiological, and ecological findings</article-title><source><italic toggle="yes">The American Journal of Tropical Medicine and Hygiene</italic></source><year>1981</year><volume>30</volume><issue>1</issue><fpage>149</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1981.30.149</pub-id><pub-id pub-id-type="pmid">6782898</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinheiro</surname><given-names>F. P.</given-names></name><name><surname>Rocha</surname><given-names>A. G.</given-names></name><name><surname>Freitas</surname><given-names>R. B.</given-names></name><etal/></person-group><article-title>Meningitis associated with Oropouche virus infections</article-title><source><italic toggle="yes">Revista do Instituto de Medicina Tropical de S&#x000e3;o Paulo</italic></source><year>1982</year><volume>24</volume><issue>4</issue><fpage>246</fpage><lpage>251</lpage><?supplied-pmid 6818668?><pub-id pub-id-type="pmid">6818668</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>R.</given-names></name><name><surname>Bueno-J&#x000fa;nior</surname><given-names>L.</given-names></name><name><surname>Ruggiero</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Spread of Oropouche virus into the central nervous system in mouse</article-title><source><italic toggle="yes">Viruses</italic></source><year>2014</year><volume>6</volume><issue>10</issue><fpage>3827</fpage><lpage>3836</lpage><pub-id pub-id-type="doi">10.3390/v6103827</pub-id><pub-id pub-id-type="other">2-s2.0-84908229983</pub-id><?supplied-pmid 25310583?><pub-id pub-id-type="pmid">25310583</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proenca-Modena</surname><given-names>J. L.</given-names></name><name><surname>Sesti-Costa</surname><given-names>R.</given-names></name><name><surname>Pinto</surname><given-names>A. K.</given-names></name><etal/></person-group><article-title>Oropouche virus infection and pathogenesis are restricted by MAVS, IRF-3, IRF-7, and type I interferon signaling pathways in nonmyeloid cells</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2015</year><volume>89</volume><issue>9</issue><fpage>4720</fpage><lpage>4737</lpage><pub-id pub-id-type="doi">10.1128/JVI.00077-15</pub-id><pub-id pub-id-type="other">2-s2.0-84928570469</pub-id><?supplied-pmid 25717109?><pub-id pub-id-type="pmid">25717109</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>C. R.</given-names></name><name><surname>Spence</surname><given-names>L.</given-names></name><name><surname>Downs</surname><given-names>W. G.</given-names></name><name><surname>Aitken</surname><given-names>T. H.</given-names></name></person-group><article-title>Oropouche virus: a new human disease agent from Trinidad, West Indies</article-title><source><italic toggle="yes">The American Journal of Tropical Medicine and Hygiene</italic></source><year>1961</year><volume>10</volume><issue>4</issue><fpage>574</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1961.10.574</pub-id><pub-id pub-id-type="pmid">13683183</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>M. R. T.</given-names></name><name><surname>Martins</surname><given-names>L. C.</given-names></name><name><surname>Rodrigues</surname><given-names>S. G.</given-names></name><etal/></person-group><article-title>Oropouche virus isolation, southeast Brazil</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2005</year><volume>11</volume><issue>10</issue><fpage>1610</fpage><lpage>1613</lpage><pub-id pub-id-type="doi">10.3201/eid1110.050464</pub-id><?supplied-pmid 16318707?><pub-id pub-id-type="pmid">16318707</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>R. M.</given-names></name></person-group><article-title>Orthobunyaviruses: recent genetic and structural insights</article-title><source><italic toggle="yes">Nature Reviews Microbiology</italic></source><year>2014</year><volume>12</volume><issue>10</issue><fpage>673</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3332</pub-id><pub-id pub-id-type="other">2-s2.0-84908658682</pub-id><?supplied-pmid 25198140?><pub-id pub-id-type="pmid">25198140</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilston-Lunel</surname><given-names>N. L.</given-names></name><name><surname>Hughes</surname><given-names>J.</given-names></name><name><surname>Acrani</surname><given-names>G. O.</given-names></name><etal/></person-group><article-title>Genetic analysis of members of the species <italic>Oropouche virus</italic> and identification of a novel M segment sequence</article-title><source><italic toggle="yes">Journal of General Virology</italic></source><year>2015</year><volume>96</volume><issue>7</issue><fpage>1636</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1099/vir.0.000108</pub-id><pub-id pub-id-type="other">2-s2.0-84938332994</pub-id><pub-id pub-id-type="pmid">25735305</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acrani</surname><given-names>G. O.</given-names></name><name><surname>Tilston-Lunel</surname><given-names>N. L.</given-names></name><name><surname>Spiegel</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Establishment of a minigenome system for Oropouche virus reveals the S genome segment to be significantly longer than reported previously</article-title><source><italic toggle="yes">Journal of General Virology</italic></source><year>2015</year><volume>96</volume><fpage>513</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000005</pub-id><pub-id pub-id-type="other">2-s2.0-84923675578</pub-id><?supplied-pmid 25491420?><pub-id pub-id-type="pmid">25491420</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinheiro</surname><given-names>F.</given-names></name><name><surname>Travassos da Rosa</surname><given-names>A.</given-names></name><name><surname>Gomes</surname><given-names>M.</given-names></name><name><surname>LeDuc</surname><given-names>J.</given-names></name><name><surname>Hoch</surname><given-names>A.</given-names></name></person-group><article-title>Transmission of Oropouche virus from man to hamster by the midge Culicoides paraensis</article-title><source><italic toggle="yes">Science</italic></source><year>1982</year><volume>215</volume><issue>4537</issue><fpage>1251</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1126/science.6800036</pub-id><pub-id pub-id-type="other">2-s2.0-0020062133</pub-id><?supplied-pmid 6800036?><pub-id pub-id-type="pmid">6800036</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoch</surname><given-names>A. L.</given-names></name><name><surname>Pinheiro</surname><given-names>F. P.</given-names></name><name><surname>Roberts</surname><given-names>D. R.</given-names></name><name><surname>Gomes</surname><given-names>M. L.</given-names></name></person-group><article-title>Laboratory transmission of Oropouche virus by <italic>Culex quinquefasciatus</italic> Say</article-title><source><italic toggle="yes">Bulletin of the Pan American Health Organization</italic></source><year>1987</year><volume>21</volume><issue>1</issue><fpage>55</fpage><lpage>61</lpage><?supplied-pmid 3607353?><pub-id pub-id-type="pmid">3607353</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreli</surname><given-names>M. L.</given-names></name><name><surname>Aquino</surname><given-names>V. H.</given-names></name><name><surname>Cruz</surname><given-names>A. C. R.</given-names></name><name><surname>Figueiredo</surname><given-names>L. T. M.</given-names></name></person-group><article-title>Diagnosis of Oropouche virus infection by RT-nested-PCR</article-title><source><italic toggle="yes">Journal of Medical Virology</italic></source><year>2002</year><volume>66</volume><issue>1</issue><fpage>139</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1002/jmv.2122</pub-id><pub-id pub-id-type="other">2-s2.0-0036186021</pub-id><?supplied-pmid 11748670?><pub-id pub-id-type="pmid">11748670</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>M. F.</given-names></name><name><surname>Nunes</surname><given-names>M.</given-names></name><name><surname>Vasconcelos</surname><given-names>P. F.</given-names></name><etal/></person-group><article-title>Diagnosis of Oropouche virus infection using a recombinant nucleocapsid protein-based enzyme immunoassay</article-title><source><italic toggle="yes">Journal of Clinical Microbiology</italic></source><year>2001</year><volume>39</volume><issue>7</issue><fpage>2445</fpage><lpage>2452</lpage><pub-id pub-id-type="doi">10.1128/JCM.39.7.2445-2452.2001</pub-id><pub-id pub-id-type="other">2-s2.0-0034962953</pub-id><?supplied-pmid 11427552?><pub-id pub-id-type="pmid">11427552</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidmann</surname><given-names>M.</given-names></name><name><surname>Rudaz</surname><given-names>V.</given-names></name><name><surname>Nunes</surname><given-names>M. R. T.</given-names></name><name><surname>Vasconcelos</surname><given-names>P. F. C.</given-names></name><name><surname>Hufert</surname><given-names>F. T.</given-names></name></person-group><article-title>Rapid detection of human pathogenic orthobunyaviruses</article-title><source><italic toggle="yes">Journal of Clinical Microbiology</italic></source><year>2003</year><volume>41</volume><issue>7</issue><fpage>3299</fpage><lpage>3305</lpage><pub-id pub-id-type="doi">10.1128/JCM.41.7.3299-3305.2003</pub-id><pub-id pub-id-type="other">2-s2.0-0037492810</pub-id><?supplied-pmid 12843078?><pub-id pub-id-type="pmid">12843078</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibrail</surname><given-names>M. M.</given-names></name><name><surname>Fiaccadori</surname><given-names>F. S.</given-names></name><name><surname>Souza</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Detection of antibodies to Oropouche virus in non-human primates in Goi&#x000e2;nia City, Goi&#x000e1;s</article-title><source><italic toggle="yes">Revista da Sociedade Brasileira de Medicina Tropical</italic></source><year>2016</year><volume>49</volume><issue>3</issue><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1590/0037-8682-0425-2015</pub-id><pub-id pub-id-type="other">2-s2.0-84976647096</pub-id><?supplied-pmid 27384834?><pub-id pub-id-type="pmid">27384834</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickett</surname><given-names>B. E.</given-names></name><name><surname>Sadat</surname><given-names>E. L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>ViPR: an open bioinformatics database and analysis resource for virology research</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2012</year><volume>40</volume><issue>D1</issue><fpage>D593</fpage><lpage>D598</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr859</pub-id><pub-id pub-id-type="other">2-s2.0-84862167820</pub-id><pub-id pub-id-type="pmid">22006842</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doytchinova</surname><given-names>I. A.</given-names></name><name><surname>Flower</surname><given-names>D. R.</given-names></name></person-group><article-title>VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2007</year><volume>8</volume><issue>1</issue><fpage>p. 4</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-8-4</pub-id><pub-id pub-id-type="other">2-s2.0-33847031827</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>M. V.</given-names></name><name><surname>Lundegaard</surname><given-names>C.</given-names></name><name><surname>Lamberth</surname><given-names>K.</given-names></name><name><surname>Buus</surname><given-names>S.</given-names></name><name><surname>Lund</surname><given-names>O.</given-names></name><name><surname>Nielsen</surname><given-names>M.</given-names></name></person-group><article-title>Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2007</year><volume>8</volume><issue>1</issue><fpage>p. 424</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-8-424</pub-id><pub-id pub-id-type="other">2-s2.0-38049169092</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>M. V.</given-names></name><name><surname>Lundegaard</surname><given-names>C.</given-names></name><name><surname>Lamberth</surname><given-names>K.</given-names></name><etal/></person-group><article-title>An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions</article-title><source><italic toggle="yes">European Journal of Immunology</italic></source><year>2005</year><volume>35</volume><issue>8</issue><fpage>2295</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1002/eji.200425811</pub-id><pub-id pub-id-type="other">2-s2.0-23844528191</pub-id><?supplied-pmid 15997466?><pub-id pub-id-type="pmid">15997466</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundegaard</surname><given-names>C.</given-names></name><name><surname>Lamberth</surname><given-names>K.</given-names></name><name><surname>Harndahl</surname><given-names>M.</given-names></name><name><surname>Buus</surname><given-names>S.</given-names></name><name><surname>Lund</surname><given-names>O.</given-names></name><name><surname>Nielsen</surname><given-names>M.</given-names></name></person-group><article-title>NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8&#x02013;11</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2008</year><volume>36</volume><issue>Supplement 2</issue><fpage>W509</fpage><lpage>W512</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn202</pub-id><pub-id pub-id-type="other">2-s2.0-48449106045</pub-id><pub-id pub-id-type="pmid">18463140</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Sidney</surname><given-names>J.</given-names></name><name><surname>Bourne</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The design and implementation of the immune epitope database and analysis resource</article-title><source><italic toggle="yes">Immunogenetics</italic></source><year>2005</year><volume>57</volume><issue>5</issue><fpage>326</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1007/s00251-005-0803-5</pub-id><pub-id pub-id-type="other">2-s2.0-21344440326</pub-id><?supplied-pmid 15895191?><pub-id pub-id-type="pmid">15895191</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Bulik</surname><given-names>S.</given-names></name><name><surname>Tampe</surname><given-names>R.</given-names></name><name><surname>van Endert</surname><given-names>P. M.</given-names></name><name><surname>Holzh&#x000fc;tter</surname><given-names>H.-G.</given-names></name></person-group><article-title>Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2003</year><volume>171</volume><issue>4</issue><fpage>1741</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.4.1741</pub-id><pub-id pub-id-type="other">2-s2.0-0041589474</pub-id><?supplied-pmid 12902473?><pub-id pub-id-type="pmid">12902473</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenzer</surname><given-names>S.</given-names></name><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Bulik</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding</article-title><source><italic toggle="yes">Cellular and Molecular Life Sciences CMLS</italic></source><year>2005</year><volume>62</volume><issue>9</issue><fpage>1025</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1007/s00018-005-4528-2</pub-id><pub-id pub-id-type="other">2-s2.0-20844434026</pub-id><?supplied-pmid 15868101?><pub-id pub-id-type="pmid">15868101</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>M.</given-names></name><name><surname>Lundegaard</surname><given-names>C.</given-names></name><name><surname>Lund</surname><given-names>O.</given-names></name></person-group><article-title>Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2007</year><volume>8</volume><issue>1</issue><fpage>p. 238</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-8-238</pub-id><pub-id pub-id-type="other">2-s2.0-34547778364</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calis</surname><given-names>J. J. A.</given-names></name><name><surname>Maybeno</surname><given-names>M.</given-names></name><name><surname>Greenbaum</surname><given-names>J. A.</given-names></name><etal/></person-group><article-title>Properties of MHC class I presented peptides that enhance immunogenicity</article-title><source><italic toggle="yes">PLoS Computational Biology</italic></source><year>2013</year><volume>9</volume><issue>10, article e1003266</issue><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003266</pub-id><pub-id pub-id-type="other">2-s2.0-84887277467</pub-id><?supplied-pmid 24204222?><pub-id pub-id-type="pmid">24204222</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitrov</surname><given-names>I.</given-names></name><name><surname>Bangov</surname><given-names>I.</given-names></name><name><surname>Flower</surname><given-names>D. R.</given-names></name><name><surname>Doytchinova</surname><given-names>I.</given-names></name></person-group><article-title>AllerTOP v.2&#x02014;a server for in silico prediction of allergens</article-title><source><italic toggle="yes">Journal of Molecular Modeling</italic></source><year>2014</year><volume>20</volume><issue>6</issue><fpage>p. 2278</fpage><pub-id pub-id-type="doi">10.1007/s00894-014-2278-5</pub-id><pub-id pub-id-type="other">2-s2.0-84901583210</pub-id><?supplied-pmid 24878803?><pub-id pub-id-type="pmid">24878803</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitrov</surname><given-names>I.</given-names></name><name><surname>Naneva</surname><given-names>L.</given-names></name><name><surname>Doytchinova</surname><given-names>I.</given-names></name><name><surname>Bangov</surname><given-names>I.</given-names></name></person-group><article-title>AllergenFP: allergenicity prediction by descriptor fingerprints</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2014</year><volume>30</volume><issue>6</issue><fpage>846</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt619</pub-id><pub-id pub-id-type="other">2-s2.0-84897585298</pub-id><?supplied-pmid 24167156?><pub-id pub-id-type="pmid">24167156</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Kapoor</surname><given-names>P.</given-names></name><name><surname>Chaudhary</surname><given-names>K.</given-names></name><etal/></person-group><article-title>In silico approach for predicting toxicity of peptides and proteins</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2013</year><volume>8</volume><issue>9, article e73957</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0073957</pub-id><pub-id pub-id-type="other">2-s2.0-84884141339</pub-id><?supplied-pmid 24058508?><pub-id pub-id-type="pmid">24058508</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Th&#x000e9;venet</surname><given-names>P.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Maupetit</surname><given-names>J.</given-names></name><name><surname>Guyon</surname><given-names>F.</given-names></name><name><surname>Derreumaux</surname><given-names>P.</given-names></name><name><surname>Tuff&#x000e9;ry</surname><given-names>P.</given-names></name></person-group><article-title>PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2012</year><volume>40</volume><issue>W1</issue><fpage>W288</fpage><lpage>W293</lpage><pub-id pub-id-type="doi">10.1093/nar/gks419</pub-id><pub-id pub-id-type="other">2-s2.0-84864452901</pub-id><pub-id pub-id-type="pmid">22581768</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Maupetit</surname><given-names>J.</given-names></name><name><surname>Derreumaux</surname><given-names>P.</given-names></name><name><surname>Tuff&#x000e9;ry</surname><given-names>P.</given-names></name></person-group><article-title>Improved PEP-FOLD approach for peptide and miniprotein structure prediction</article-title><source><italic toggle="yes">Journal of Chemical Theory and Computation</italic></source><year>2014</year><volume>10</volume><issue>10</issue><fpage>4745</fpage><lpage>4758</lpage><pub-id pub-id-type="doi">10.1021/ct500592m</pub-id><pub-id pub-id-type="other">2-s2.0-84907997286</pub-id><?supplied-pmid 26588162?><pub-id pub-id-type="pmid">26588162</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>G. M.</given-names></name><name><surname>Huey</surname><given-names>R.</given-names></name><name><surname>Lindstrom</surname><given-names>W.</given-names></name><etal/></person-group><article-title>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</article-title><source><italic toggle="yes">Journal of Computational Chemistry</italic></source><year>2009</year><volume>30</volume><issue>16</issue><fpage>2785</fpage><lpage>2791</lpage><pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><pub-id pub-id-type="other">2-s2.0-70349932423</pub-id><?supplied-pmid 19399780?><pub-id pub-id-type="pmid">19399780</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O.</given-names></name><name><surname>Olson</surname><given-names>A. J.</given-names></name></person-group><article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source><italic toggle="yes">Journal of Computational Chemistry</italic></source><year>2010</year><volume>31</volume><issue>2</issue><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="other">2-s2.0-76149120388</pub-id><?supplied-pmid 19499576?><pub-id pub-id-type="pmid">19499576</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gras</surname><given-names>S.</given-names></name><name><surname>Kedzierski</surname><given-names>L.</given-names></name><name><surname>Valkenburg</surname><given-names>S. A.</given-names></name><etal/></person-group><article-title>Cross-reactive CD8<sup>+</sup> T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2010</year><volume>107</volume><issue>28</issue><fpage>12599</fpage><lpage>12604</lpage><pub-id pub-id-type="doi">10.1073/pnas.1007270107</pub-id><pub-id pub-id-type="other">2-s2.0-77955462803</pub-id><pub-id pub-id-type="pmid">20616031</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>M. C.</given-names></name><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Nielsen</surname><given-names>M.</given-names></name><name><surname>Marcatili</surname><given-names>P.</given-names></name></person-group><article-title>BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2017</year><volume>45</volume><issue>W1</issue><fpage>W24</fpage><lpage>W29</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx346</pub-id><pub-id pub-id-type="other">2-s2.0-85021067063</pub-id><?supplied-pmid 28472356?><pub-id pub-id-type="pmid">28472356</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>H.</given-names></name><name><surname>Ansari</surname><given-names>H. R.</given-names></name><name><surname>Raghava</surname><given-names>G. P. S.</given-names></name></person-group><article-title>Improved method for linear B-cell epitope prediction using antigen&#x02019;s primary sequence</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2013</year><volume>8</volume><issue>5, article e62216</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0062216</pub-id><pub-id pub-id-type="other">2-s2.0-84877146650</pub-id><?supplied-pmid 23667458?><pub-id pub-id-type="pmid">23667458</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponomarenko</surname><given-names>J.</given-names></name><name><surname>Bui</surname><given-names>H.-H.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group><article-title>ElliPro: a new structure-based tool for the prediction of antibody epitopes</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2008</year><volume>9</volume><issue>1</issue><fpage>p. 514</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-9-514</pub-id><pub-id pub-id-type="other">2-s2.0-58049187138</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gasteiger</surname><given-names>E.</given-names></name><name><surname>Hoogland</surname><given-names>C.</given-names></name><name><surname>Gattiker</surname><given-names>A.</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Walker</surname><given-names>J. M.</given-names></name></person-group><article-title>Protein identification and analysis tools on the ExPASy server</article-title><source><italic toggle="yes">The Proteomics Protocols Handbook</italic></source><year>2005</year><publisher-loc>Totowa, NJ, USA</publisher-loc><publisher-name>Humana Press</publisher-name><fpage>571</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1385/1-59259-890-0:571</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuffin</surname><given-names>L. J.</given-names></name><name><surname>Bryson</surname><given-names>K.</given-names></name><name><surname>Jones</surname><given-names>D. T.</given-names></name></person-group><article-title>The PSIPRED protein structure prediction server</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2000</year><volume>16</volume><issue>4</issue><fpage>404</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/16.4.404</pub-id><pub-id pub-id-type="other">2-s2.0-0034044314</pub-id><?supplied-pmid 10869041?><pub-id pub-id-type="pmid">10869041</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>D. T.</given-names></name><name><surname>Cozzetto</surname><given-names>D.</given-names></name></person-group><article-title>DISOPRED3: precise disordered region predictions with annotated protein-binding activity</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2015</year><volume>31</volume><issue>6</issue><fpage>857</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu744</pub-id><pub-id pub-id-type="other">2-s2.0-84925251625</pub-id><?supplied-pmid 25391399?><pub-id pub-id-type="pmid">25391399</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>A.</given-names></name><name><surname>Kucukural</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>I-TASSER: a unified platform for automated protein structure and function prediction</article-title><source><italic toggle="yes">Nature Protocols</italic></source><year>2010</year><volume>5</volume><issue>4</issue><fpage>725</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1038/nprot.2010.5</pub-id><pub-id pub-id-type="other">2-s2.0-77954065271</pub-id><?supplied-pmid 20360767?><pub-id pub-id-type="pmid">20360767</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>I-TASSER server for protein 3D structure prediction</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2008</year><volume>9</volume><issue>1</issue><fpage>p. 40</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-9-40</pub-id><pub-id pub-id-type="other">2-s2.0-39449115394</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization</article-title><source><italic toggle="yes">Biophysical Journal</italic></source><year>2011</year><volume>101</volume><issue>10</issue><fpage>2525</fpage><lpage>2534</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2011.10.024</pub-id><pub-id pub-id-type="other">2-s2.0-81255123286</pub-id><?supplied-pmid 22098752?><pub-id pub-id-type="pmid">22098752</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guex</surname><given-names>N.</given-names></name><name><surname>Peitsch</surname><given-names>M. C.</given-names></name><name><surname>Schwede</surname><given-names>T.</given-names></name></person-group><article-title>Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective</article-title><source><italic toggle="yes">Electrophoresis</italic></source><year>2009</year><volume>30</volume><issue>S1</issue><fpage>S162</fpage><lpage>S173</lpage><pub-id pub-id-type="doi">10.1002/elps.200900140</pub-id><pub-id pub-id-type="other">2-s2.0-69249212321</pub-id><pub-id pub-id-type="pmid">19517507</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiederstein</surname><given-names>M.</given-names></name><name><surname>Sippl</surname><given-names>M. J.</given-names></name></person-group><article-title>ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2007</year><volume>35</volume><issue>Supplement 2</issue><fpage>W407</fpage><lpage>W410</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm290</pub-id><pub-id pub-id-type="other">2-s2.0-34547566446</pub-id><pub-id pub-id-type="pmid">17517781</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benkert</surname><given-names>P.</given-names></name><name><surname>K&#x000fc;nzli</surname><given-names>M.</given-names></name><name><surname>Schwede</surname><given-names>T.</given-names></name></person-group><article-title>QMEAN server for protein model quality estimation</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2009</year><volume>37</volume><issue>Supplement 2</issue><fpage>W510</fpage><lpage>W514</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp322</pub-id><pub-id pub-id-type="other">2-s2.0-67650358909</pub-id><pub-id pub-id-type="pmid">19429685</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallner</surname><given-names>B.</given-names></name><name><surname>Elofsson</surname><given-names>A.</given-names></name></person-group><article-title>Can correct protein models be identified?</article-title><source><italic toggle="yes">Protein Science</italic></source><year>2003</year><volume>12</volume><issue>5</issue><fpage>1073</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1110/ps.0236803</pub-id><pub-id pub-id-type="other">2-s2.0-0037406141</pub-id><?supplied-pmid 12717029?><pub-id pub-id-type="pmid">12717029</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Beer</surname><given-names>T. A. P.</given-names></name><name><surname>Berka</surname><given-names>K.</given-names></name><name><surname>Thornton</surname><given-names>J. M.</given-names></name><name><surname>Laskowski</surname><given-names>R. A.</given-names></name></person-group><article-title>PDBsum additions</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2014</year><volume>42</volume><issue>D1</issue><fpage>D292</fpage><lpage>D296</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt940</pub-id><pub-id pub-id-type="other">2-s2.0-84891820493</pub-id><pub-id pub-id-type="pmid">24153109</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhikari</surname><given-names>U. K.</given-names></name><name><surname>Rahman</surname><given-names>M. M.</given-names></name></person-group><article-title>Comparative analysis of amino acid composition in the active site of <italic>nir</italic>k gene encoding copper-containing nitrite reductase (CuNiR) in bacterial spp.</article-title><source><italic toggle="yes">Computational Biology and Chemistry</italic></source><year>2017</year><volume>67</volume><fpage>102</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.compbiolchem.2016.12.011</pub-id><pub-id pub-id-type="other">2-s2.0-85008425635</pub-id><?supplied-pmid 28068515?><pub-id pub-id-type="pmid">28068515</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castrignan&#x000f2;</surname><given-names>T.</given-names></name><name><surname>De Meo</surname><given-names>P. D.</given-names></name><name><surname>Cozzetto</surname><given-names>D.</given-names></name><name><surname>Talamo</surname><given-names>I. G.</given-names></name><name><surname>Tramontano</surname><given-names>A.</given-names></name></person-group><article-title>The PMDB protein model database</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2006</year><volume>34</volume><issue>90001</issue><supplement>Supplement 1</supplement><fpage>D306</fpage><lpage>D309</lpage><pub-id pub-id-type="doi">10.1093/nar/gkj105</pub-id><pub-id pub-id-type="pmid">16381873</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>M.</given-names></name><name><surname>Ghersi</surname><given-names>D.</given-names></name><name><surname>Sanchez</surname><given-names>R.</given-names></name></person-group><article-title>SITEHOUND-web: a server for ligand binding site identification in protein structures</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2009</year><volume>37</volume><issue>Supplement 2</issue><fpage>W413</fpage><lpage>W416</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp281</pub-id><pub-id pub-id-type="other">2-s2.0-67849097355</pub-id><pub-id pub-id-type="pmid">19398430</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeever</surname><given-names>T. M.</given-names></name><name><surname>Lewis</surname><given-names>S. A.</given-names></name><name><surname>Smith</surname><given-names>C.</given-names></name><name><surname>Hubbard</surname><given-names>R.</given-names></name></person-group><article-title>Vaccination and allergic disease: a birth cohort study</article-title><source><italic toggle="yes">American Journal of Public Health</italic></source><year>2004</year><volume>94</volume><issue>6</issue><fpage>985</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.2105/AJPH.94.6.985</pub-id><pub-id pub-id-type="other">2-s2.0-2542480958</pub-id><?supplied-pmid 15249303?><pub-id pub-id-type="pmid">15249303</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>P.</given-names></name><name><surname>Ju</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Bioinformatics resources and tools for conformational B-cell epitope prediction</article-title><source><italic toggle="yes">Computational and Mathematical Methods in Medicine</italic></source><year>2013</year><volume>2013</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1155/2013/943636</pub-id><pub-id pub-id-type="other">2-s2.0-84881493614</pub-id><pub-id pub-id-type="publisher-id">943636</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Regenmortel</surname><given-names>M. H. V.</given-names></name></person-group><article-title>Antigenicity and immunogenicity of synthetic peptides</article-title><source><italic toggle="yes">Biologicals</italic></source><year>2001</year><volume>29</volume><issue>3-4</issue><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1006/biol.2001.0308</pub-id><pub-id pub-id-type="other">2-s2.0-0035699903</pub-id><?supplied-pmid 11851317?><pub-id pub-id-type="pmid">11851317</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mar&#x000ed;a</surname><given-names>R. A. R.</given-names></name><name><surname>Arturo</surname><given-names>C. V. J.</given-names></name><name><surname>Alicia</surname><given-names>J. A.</given-names></name><name><surname>Paulina</surname><given-names>M. L. G.</given-names></name><name><surname>Gerardo</surname><given-names>A. O.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Afrin</surname><given-names>F.</given-names></name><name><surname>Hemeg</surname><given-names>H.</given-names></name><name><surname>Ozbak</surname><given-names>H.</given-names></name></person-group><article-title>The impact of bioinformatics on vaccine design and development</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2017</year><publisher-loc>Rijeka, Croatia</publisher-loc><publisher-name>InTech</publisher-name><pub-id pub-id-type="doi">10.5772/intechopen.69273</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seib</surname><given-names>K. L.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Rappuoli</surname><given-names>R.</given-names></name></person-group><article-title>Developing vaccines in the era of genomics: a decade of reverse vaccinology</article-title><source><italic toggle="yes">Clinical Microbiology and Infection</italic></source><year>2012</year><volume>18</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2012.03939.x</pub-id><pub-id pub-id-type="other">2-s2.0-84867397072</pub-id><?supplied-pmid 22882709?><pub-id pub-id-type="pmid">22882709</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Groot</surname><given-names>A. S.</given-names></name><name><surname>Rappuoli</surname><given-names>R.</given-names></name></person-group><article-title>Genome-derived vaccines</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2004</year><volume>3</volume><issue>1</issue><fpage>59</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1586/14760584.3.1.59</pub-id><pub-id pub-id-type="other">2-s2.0-1042298565</pub-id><pub-id pub-id-type="pmid">14761244</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korber</surname><given-names>B.</given-names></name><name><surname>LaBute</surname><given-names>M.</given-names></name><name><surname>Yusim</surname><given-names>K.</given-names></name></person-group><article-title>Immunoinformatics comes of age</article-title><source><italic toggle="yes">PLoS Computational Biology</italic></source><year>2006</year><volume>2</volume><issue>6, article e71</issue><pub-id pub-id-type="doi">10.1371/journal.pcbi.0020071</pub-id><pub-id pub-id-type="other">2-s2.0-33745608737</pub-id><?supplied-pmid 16846250?><pub-id pub-id-type="pmid">16846250</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>A. W.</given-names></name><name><surname>McCluskey</surname><given-names>J.</given-names></name><name><surname>Rossjohn</surname><given-names>J.</given-names></name></person-group><article-title>More than one reason to rethink the use of peptides in vaccine design</article-title><source><italic toggle="yes">Nature Reviews Drug Discovery</italic></source><year>2007</year><volume>6</volume><issue>5</issue><fpage>404</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/nrd2224</pub-id><pub-id pub-id-type="other">2-s2.0-34247891741</pub-id><?supplied-pmid 17473845?><pub-id pub-id-type="pmid">17473845</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>R.</given-names></name><name><surname>Gray</surname><given-names>D.</given-names></name></person-group><article-title>Immunological memory and protective immunity: understanding their relation</article-title><source><italic toggle="yes">Science</italic></source><year>1996</year><volume>272</volume><issue>5258</issue><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1126/science.272.5258.54</pub-id><pub-id pub-id-type="other">2-s2.0-0030001674</pub-id><?supplied-pmid 8600537?><pub-id pub-id-type="pmid">8600537</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanna</surname><given-names>I. J.</given-names></name><name><surname>Carlson</surname><given-names>N. E.</given-names></name><name><surname>Slifka</surname><given-names>M. K.</given-names></name></person-group><article-title>Duration of humoral immunity to common viral and vaccine antigens</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2007</year><volume>357</volume><issue>19</issue><fpage>1903</fpage><lpage>1915</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa066092</pub-id><pub-id pub-id-type="other">2-s2.0-35848969753</pub-id><?supplied-pmid 17989383?><pub-id pub-id-type="pmid">17989383</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slifka</surname><given-names>M.</given-names></name><name><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity</article-title><source><italic toggle="yes">Trends in Microbiology</italic></source><year>1996</year><volume>4</volume><issue>10</issue><fpage>394</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/0966-842X(96)10059-7</pub-id><pub-id pub-id-type="other">2-s2.0-0030271822</pub-id><?supplied-pmid 8899965?><pub-id pub-id-type="pmid">8899965</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tesh</surname><given-names>R. B.</given-names></name><name><surname>Vasconcelos</surname><given-names>P. F. C.</given-names></name></person-group><article-title>Sandfly fever, Oropouche fever, and other bunyavirus infections</article-title><source><italic toggle="yes">Tropical Infectious Diseases: Principles, Pathogens and Practice</italic></source><year>2011</year><edition>Third</edition><publisher-loc>Philadelphia, PA, USA</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>481</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/B978-0-7020-3935-5.00072-0</pub-id><pub-id pub-id-type="other">2-s2.0-84885109842</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorner</surname><given-names>T.</given-names></name><name><surname>Radbruch</surname><given-names>A.</given-names></name></person-group><article-title>Antibodies and B cell memory in viral immunity</article-title><source><italic toggle="yes">Immunity</italic></source><year>2007</year><volume>27</volume><issue>3</issue><fpage>384</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2007.09.002</pub-id><pub-id pub-id-type="other">2-s2.0-34548660561</pub-id><?supplied-pmid 17892847?><pub-id pub-id-type="pmid">17892847</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>R. M.</given-names></name><name><surname>Selin</surname><given-names>L. K.</given-names></name><name><surname>Szomolanyi-Tsuda</surname><given-names>E.</given-names></name></person-group><article-title>Immunological memory to viral infections</article-title><source><italic toggle="yes">Annual Review of Immunology</italic></source><year>2004</year><volume>22</volume><issue>1</issue><fpage>711</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104527</pub-id><pub-id pub-id-type="other">2-s2.0-1642431348</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>K.-Y. A.</given-names></name><name><surname>Li</surname><given-names>C. K. F.</given-names></name><name><surname>Clutterbuck</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2014</year><volume>209</volume><issue>9</issue><fpage>1354</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit650</pub-id><pub-id pub-id-type="other">2-s2.0-84898849416</pub-id><?supplied-pmid 24415790?><pub-id pub-id-type="pmid">24415790</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebeis</surname><given-names>B. J.</given-names></name><name><surname>Klenovsek</surname><given-names>K.</given-names></name><name><surname>Rohwer</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Activation of virus-specific memory B cells in the absence of T cell help</article-title><source><italic toggle="yes">Journal of Experimental Medicine</italic></source><year>2004</year><volume>199</volume><issue>4</issue><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1084/jem.20030091</pub-id><pub-id pub-id-type="other">2-s2.0-1242343665</pub-id><?supplied-pmid 14769849?><pub-id pub-id-type="pmid">14769849</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandermeulen</surname><given-names>C.</given-names></name><name><surname>Verhoye</surname><given-names>L.</given-names></name><name><surname>Vaidya</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Detection of mumps virus-specific memory B cells by transfer of peripheral blood mononuclear cells into immune-deficient mice</article-title><source><italic toggle="yes">Immunology</italic></source><year>2010</year><volume>131</volume><issue>1</issue><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2010.03263.x</pub-id><pub-id pub-id-type="other">2-s2.0-77955149480</pub-id><?supplied-pmid 20586811?><pub-id pub-id-type="pmid">20586811</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>H. M.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Sundararajan</surname><given-names>A.</given-names></name><name><surname>Huan</surname><given-names>L.</given-names></name><name><surname>Sangster</surname><given-names>M. Y.</given-names></name></person-group><article-title>Quantitative analysis of influenza virus-specific B cell memory generated by different routes of inactivated virus vaccination</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2010</year><volume>28</volume><issue>10</issue><fpage>2186</fpage><lpage>2194</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.12.058</pub-id><pub-id pub-id-type="other">2-s2.0-77049112017</pub-id><?supplied-pmid 20056191?><pub-id pub-id-type="pmid">20056191</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narvaez</surname><given-names>C. F.</given-names></name><name><surname>Feng</surname><given-names>N.</given-names></name><name><surname>Vasquez</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Human rotavirus-specific IgM memory B cells have differential cloning efficiencies and switch capacities and play a role in antiviral immunity in vivo</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2012</year><volume>86</volume><issue>19</issue><fpage>10829</fpage><lpage>10840</lpage><pub-id pub-id-type="doi">10.1128/JVI.01466-12</pub-id><pub-id pub-id-type="other">2-s2.0-84869015894</pub-id><?supplied-pmid 22855480?><pub-id pub-id-type="pmid">22855480</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>D.</given-names></name><name><surname>Rojas</surname><given-names>O. L.</given-names></name><name><surname>Duarte-Rey</surname><given-names>C.</given-names></name><name><surname>Mantilla</surname><given-names>R. D.</given-names></name><name><surname>&#x000c1;ngel</surname><given-names>J.</given-names></name><name><surname>Franco</surname><given-names>M. A.</given-names></name></person-group><article-title>Simultaneous assessment of rotavirus-specific memory B cells and serological memory after B cell depletion therapy with rituximab</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2014</year><volume>9</volume><issue>5, article e97087</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0097087</pub-id><pub-id pub-id-type="other">2-s2.0-84901285765</pub-id><?supplied-pmid 24819618?><pub-id pub-id-type="pmid">24819618</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>S. A.</given-names></name><name><surname>de Alwis</surname><given-names>A. R.</given-names></name><name><surname>Kose</surname><given-names>N.</given-names></name><name><surname>Jadi</surname><given-names>R. S.</given-names></name><name><surname>de Silva</surname><given-names>A. M.</given-names></name><name><surname>Crowe</surname><given-names>J. E.</given-names></name></person-group><article-title>Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2014</year><volume>88</volume><issue>21</issue><fpage>12233</fpage><lpage>12241</lpage><pub-id pub-id-type="doi">10.1128/JVI.00247-14</pub-id><pub-id pub-id-type="other">2-s2.0-84907979176</pub-id><?supplied-pmid 25100837?><pub-id pub-id-type="pmid">25100837</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilston-Lunel</surname><given-names>N. L.</given-names></name><name><surname>Acrani</surname><given-names>G. O.</given-names></name><name><surname>Randall</surname><given-names>R. E.</given-names></name><name><surname>Elliott</surname><given-names>R. M.</given-names></name></person-group><article-title>Generation of recombinant Oropouche viruses lacking the nonstructural protein NSm or NSs</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2016</year><volume>90</volume><issue>5</issue><fpage>2616</fpage><lpage>2627</lpage><pub-id pub-id-type="doi">10.1128/JVI.02849-15</pub-id><pub-id pub-id-type="other">2-s2.0-84961167427</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esser</surname><given-names>M. T.</given-names></name><name><surname>Marchese</surname><given-names>R. D.</given-names></name><name><surname>Kierstead</surname><given-names>L. S.</given-names></name><etal/></person-group><article-title>Memory T cells and vaccines</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2003</year><volume>21</volume><issue>5-6</issue><fpage>419</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00407-3</pub-id><pub-id pub-id-type="other">2-s2.0-0037449486</pub-id><?supplied-pmid 12531640?><pub-id pub-id-type="pmid">12531640</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>M. V.</given-names></name><name><surname>Lelic</surname><given-names>A.</given-names></name><name><surname>Parsons</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Identification of CD8<sup>+</sup> T cell epitopes in the West Nile virus polyprotein by reverse-immunology using NetCTL</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2010</year><volume>5</volume><issue>9, article e12697</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0012697</pub-id><pub-id pub-id-type="other">2-s2.0-77958601263</pub-id><?supplied-pmid 20856867?><pub-id pub-id-type="pmid">20856867</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>A.</given-names></name><name><surname>Ali</surname><given-names>S.</given-names></name><name><surname>Ahamad</surname><given-names>S.</given-names></name><name><surname>Malik</surname><given-names>M. Z.</given-names></name><name><surname>Ishrat</surname><given-names>R.</given-names></name></person-group><article-title>From ZikV genome to vaccine: in silico approach for the epitope-based peptide vaccine against Zika virus envelope glycoprotein</article-title><source><italic toggle="yes">Immunology</italic></source><year>2016</year><volume>149</volume><issue>4</issue><fpage>386</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1111/imm.12656</pub-id><pub-id pub-id-type="other">2-s2.0-84986274006</pub-id><?supplied-pmid 27485738?><pub-id pub-id-type="pmid">27485738</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>S.</given-names></name><name><surname>Chakravorty</surname><given-names>R.</given-names></name><name><surname>Ahmed</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A computational approach for identification of epitopes in dengue virus envelope protein: a step towards designing a universal dengue vaccine targeting endemic regions</article-title><source><italic toggle="yes">In Silico Biology</italic></source><year>2010</year><volume>10</volume><issue>5-6</issue><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.3233/ISB-2010-0435</pub-id><pub-id pub-id-type="other">2-s2.0-82555195175</pub-id><?supplied-pmid 22430357?><pub-id pub-id-type="pmid">22430357</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>M. A.</given-names></name><name><surname>Khan</surname><given-names>M. A.</given-names></name><name><surname>Datta</surname><given-names>A.</given-names></name><name><surname>Mazumder</surname><given-names>M. H. H.</given-names></name><name><surname>Hossain</surname><given-names>M. U.</given-names></name></person-group><article-title>A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment</article-title><source><italic toggle="yes">Molecular Immunology</italic></source><year>2015</year><volume>65</volume><issue>1</issue><fpage>189</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2014.12.013</pub-id><pub-id pub-id-type="other">2-s2.0-84922754421</pub-id><?supplied-pmid 25682054?><pub-id pub-id-type="pmid">25682054</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhikari</surname><given-names>U. K.</given-names></name><name><surname>Rahman</surname><given-names>M. M.</given-names></name></person-group><article-title>Overlapping CD8 + and CD4 + T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach</article-title><source><italic toggle="yes">Infection, Genetics and Evolution</italic></source><year>2017</year><volume>56</volume><fpage>75</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2017.10.022</pub-id><pub-id pub-id-type="other">2-s2.0-85032437206</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oany</surname><given-names>A. R.</given-names></name><name><surname>Pervin</surname><given-names>T.</given-names></name><name><surname>Mia</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Vaccinomics approach for designing potential peptide vaccine by targeting <italic>Shigella</italic> spp. serine protease autotransporter subfamily protein SigA</article-title><source><italic toggle="yes">Journal of Immunology Research</italic></source><year>2017</year><volume>2017</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1155/2017/6412353</pub-id><pub-id pub-id-type="other">2-s2.0-85029720873</pub-id><pub-id pub-id-type="publisher-id">6412353</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossain</surname><given-names>M. U.</given-names></name><name><surname>Hashem</surname><given-names>A.</given-names></name><name><surname>Keya</surname><given-names>C. A.</given-names></name><name><surname>Salimullah</surname><given-names>M.</given-names></name></person-group><article-title>Therapeutics insight with inclusive immunopharmacology explication of human rotavirus a for the treatment of diarrhea</article-title><source><italic toggle="yes">Frontiers in Pharmacology</italic></source><year>2016</year><volume>7</volume><fpage>p. 153</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00153</pub-id><pub-id pub-id-type="other">2-s2.0-84977619135</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Freitas e Silva</surname><given-names>R.</given-names></name><name><surname>Ferreira</surname><given-names>L. F. G. R.</given-names></name><name><surname>Hernandes</surname><given-names>M. Z.</given-names></name><etal/></person-group><article-title>Combination of in silico methods in the search for potential CD4<sup>+</sup> and CD8<sup>+</sup> T cell epitopes in the proteome of <italic>Leishmania braziliensis</italic>
</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2016</year><volume>7</volume><fpage>p. 327</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00327</pub-id><pub-id pub-id-type="other">2-s2.0-84991320859</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M. K.</given-names></name><name><surname>Zaman</surname><given-names>S.</given-names></name><name><surname>Chakraborty</surname><given-names>S.</given-names></name><etal/></person-group><article-title>In silico predicted mycobacterial epitope elicits in vitro T-cell responses</article-title><source><italic toggle="yes">Molecular Immunology</italic></source><year>2014</year><volume>61</volume><issue>1</issue><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2014.04.009</pub-id><pub-id pub-id-type="other">2-s2.0-84900851672</pub-id><?supplied-pmid 24853589?><pub-id pub-id-type="pmid">24853589</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maenaka</surname><given-names>K.</given-names></name><name><surname>Jones</surname><given-names>E. Y.</given-names></name></person-group><article-title>MHC superfamily structure and the immune system</article-title><source><italic toggle="yes">Current Opinion in Structural Biology</italic></source><year>1999</year><volume>9</volume><issue>6</issue><fpage>745</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1016/S0959-440X(99)00039-1</pub-id><pub-id pub-id-type="other">2-s2.0-0032761773</pub-id><?supplied-pmid 10607669?><pub-id pub-id-type="pmid">10607669</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>L. J.</given-names></name><name><surname>Wiley</surname><given-names>D. C.</given-names></name></person-group><article-title>Antigenic peptide binding by class I and class II histocompatibility proteins</article-title><source><italic toggle="yes">Structure</italic></source><year>1994</year><volume>2</volume><issue>4</issue><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/S0969-2126(00)00026-5</pub-id><pub-id pub-id-type="other">2-s2.0-0028773294</pub-id><?supplied-pmid 8087551?><pub-id pub-id-type="pmid">8087551</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tshabalala</surname><given-names>M.</given-names></name><name><surname>Mellet</surname><given-names>J.</given-names></name><name><surname>Pepper</surname><given-names>M. S.</given-names></name></person-group><article-title>Human leukocyte antigen diversity: a southern African perspective</article-title><source><italic toggle="yes">Journal of Immunology Research</italic></source><year>2015</year><volume>2015</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1155/2015/746151</pub-id><pub-id pub-id-type="other">2-s2.0-84940416952</pub-id><pub-id pub-id-type="publisher-id">746151</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>K.</given-names></name><name><surname>Moormann</surname><given-names>A. M.</given-names></name><name><surname>Lyke</surname><given-names>K. E.</given-names></name><etal/></person-group><article-title>Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci</article-title><source><italic toggle="yes">Tissue Antigens</italic></source><year>2004</year><volume>63</volume><issue>4</issue><fpage>293</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1111/j.0001-2815.2004.00192.x</pub-id><pub-id pub-id-type="other">2-s2.0-12144291194</pub-id><?supplied-pmid 15009803?><pub-id pub-id-type="pmid">15009803</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paximadis</surname><given-names>M.</given-names></name><name><surname>Mathebula</surname><given-names>T. Y.</given-names></name><name><surname>Gentle</surname><given-names>N. L.</given-names></name><etal/></person-group><article-title>Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the black and Caucasian South African population</article-title><source><italic toggle="yes">Human Immunology</italic></source><year>2012</year><volume>73</volume><issue>1</issue><fpage>80</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2011.10.013</pub-id><pub-id pub-id-type="other">2-s2.0-84355161411</pub-id><?supplied-pmid 22074999?><pub-id pub-id-type="pmid">22074999</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guruprasad</surname><given-names>K.</given-names></name><name><surname>Reddy</surname><given-names>B. V. B.</given-names></name><name><surname>Pandit</surname><given-names>M. W.</given-names></name></person-group><article-title>Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence</article-title><source><italic toggle="yes">Protein Engineering, Design and Selection</italic></source><year>1990</year><volume>4</volume><issue>2</issue><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1093/protein/4.2.155</pub-id><pub-id pub-id-type="other">2-s2.0-0025612425</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jenssen</surname><given-names>H.</given-names></name><name><surname>Aspmo</surname><given-names>S. I.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Otvos</surname><given-names>L.</given-names></name></person-group><article-title>Serum stability of peptides</article-title><source><italic toggle="yes">Peptide-Based Drug Design</italic></source><year>2008</year><publisher-loc>Totowa, NJ, USA</publisher-loc><publisher-name>Humana Press</publisher-name><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1007/978-1-59745-419-3_10</pub-id><pub-id pub-id-type="other">2-s2.0-84934439926</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathur</surname><given-names>D.</given-names></name><name><surname>Prakash</surname><given-names>S.</given-names></name><name><surname>Anand</surname><given-names>P.</given-names></name><etal/></person-group><article-title>PEPlife: a repository of the half-life of peptides</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2016</year><volume>6</volume><issue>1, article 36617</issue><pub-id pub-id-type="doi">10.1038/srep36617</pub-id><pub-id pub-id-type="other">2-s2.0-84994408880</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhanda</surname><given-names>S. K.</given-names></name><name><surname>Vir</surname><given-names>P.</given-names></name><name><surname>Raghava</surname><given-names>G. P. S.</given-names></name></person-group><article-title>Designing of interferon-gamma inducing MHC class-II binders</article-title><source><italic toggle="yes">Biology Direct</italic></source><year>2013</year><volume>8</volume><issue>1</issue><fpage>p. 30</fpage><pub-id pub-id-type="doi">10.1186/1745-6150-8-30</pub-id><pub-id pub-id-type="other">2-s2.0-84889053011</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhanda</surname><given-names>S. K.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Vir</surname><given-names>P.</given-names></name><name><surname>Raghava</surname><given-names>G. P. S.</given-names></name></person-group><article-title>Prediction of IL4 inducing peptides</article-title><source><italic toggle="yes">Clinical and Developmental Immunology</italic></source><year>2013</year><volume>2013, article 263952</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1155/2013/263952</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>G.</given-names></name><name><surname>Usmani</surname><given-names>S. S.</given-names></name><name><surname>Dhanda</surname><given-names>S. K.</given-names></name><etal/></person-group><article-title>Computer-aided designing of immunosuppressive peptides based on IL-10 inducing potential</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2017</year><volume>7</volume><issue>1, article 42851</issue><pub-id pub-id-type="doi">10.1038/srep42851</pub-id><pub-id pub-id-type="other">2-s2.0-85013191710</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Nguyen</surname><given-names>M. T.</given-names></name></person-group><article-title>Recent advances of vaccine adjuvants for infectious diseases</article-title><source><italic toggle="yes">Immune Network</italic></source><year>2015</year><volume>15</volume><issue>2</issue><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.4110/in.2015.15.2.51</pub-id><?supplied-pmid 25922593?><pub-id pub-id-type="pmid">25922593</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonam</surname><given-names>S. R.</given-names></name><name><surname>Partidos</surname><given-names>C. D.</given-names></name><name><surname>Halmuthur</surname><given-names>S. K. M.</given-names></name><name><surname>Muller</surname><given-names>S.</given-names></name></person-group><article-title>An overview of novel adjuvants designed for improving vaccine efficacy</article-title><source><italic toggle="yes">Trends in Pharmacological Sciences</italic></source><year>2017</year><volume>38</volume><issue>9</issue><fpage>771</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.06.002</pub-id><pub-id pub-id-type="other">2-s2.0-85021342371</pub-id><?supplied-pmid 28668223?><pub-id pub-id-type="pmid">28668223</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schijns</surname><given-names>V. E. J. C.</given-names></name><name><surname>Lavelle</surname><given-names>E. C.</given-names></name></person-group><article-title>Trends in vaccine adjuvants</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2011</year><volume>10</volume><issue>4</issue><fpage>539</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1586/erv.11.21</pub-id><pub-id pub-id-type="other">2-s2.0-79955083788</pub-id><pub-id pub-id-type="pmid">21506650</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Schematic representation of epitope-based vaccine design and ligand-binding pocket prediction against the OROV polyprotein.</p></caption><graphic xlink:href="JIR2018-6718083.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Population coverage of the epitopes and their respective HLA alleles of the OROV polyprotein. The epitopes with different HLA-binding specificities increase the population coverage as the several HLA types are expressed at radically different frequencies in various ethnicities.</p></caption><graphic xlink:href="JIR2018-6718083.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Docking simulation study (sample). (a) The docking results as the surface structure of the MHC-I HLA allele &#x0201c;HLA-B<sup>&#x02217;</sup>35:01&#x0201d; (tint light pink color) and the sticky form of epitope &#x0201c;TSSWGCEEY&#x0201d; (orange olive color). The black color box represents the position of epitope in the surface structure. (b) Epitope in the cartoon structure. (c) Sticky form of epitope &#x0201c;TSSWGCEEY&#x0201d; (orange olive color) with residue's position. (d) Binding interaction of the epitope residues and the HLA-B<sup>&#x02217;</sup>35:01 residues through the hydrogen bonds. Hydrogen bonds and the distances are shown in green color. (e) The docking results as the surface structure of the MHC-I HLA allele &#x0201c;HLA-B<sup>&#x02217;</sup>35:01&#x0201d; (tint light blue color) and the sticky form of epitope &#x0201c;LAIDTGCLY&#x0201d; (orange olive color). The black color box represents the position of epitope in the surface structure. (f) Epitope LAIDTGCLY in the cartoon structure. (g) Sticky form of epitope &#x0201c;LAIDTGCLY&#x0201d; (orange olive color) with residue's position. (h) Binding interaction of the epitope residues and the HLA-B<sup>&#x02217;</sup>35:01 residues through the hydrogen bonds. Hydrogen bonds and the distances are shown in green color.</p></caption><graphic xlink:href="JIR2018-6718083.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Docking simulation study. (a) The docking results as the surface structure of the MHC-II (HLA-DR) (lime green color) and the sticky form of epitope &#x0201c;LAIDTGCLY&#x0201d; (red color). Black color box represents the position of epitope in the surface structure. (b) Epitope in the cartoon structure. (c) Sticky form of epitope &#x0201c;LAIDTGCLY&#x0201d; (red color) with residue position. (d) Binding interaction of the epitope residues and the HLA-DR residues through the hydrogen bonds. Hydrogen bonds and the distances are shown in green color.</p></caption><graphic xlink:href="JIR2018-6718083.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Three-dimensional representation of conformational or discontinuous epitopes (a&#x02013;h) of the highest antigenic polyprotein of OROV. The epitopes are represented by yellow surface, and the bulk of the polyprotein is represented in grey sticks.</p></caption><graphic xlink:href="JIR2018-6718083.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Disordered regions of the OROV polyprotein. Here, amino acids in the input sequence are considered disordered when the blue line is above the grey dashed line, that is, the confidence score is higher than 0.5. The orange line shows the confidence of disordered protein-binding residue predictions.</p></caption><graphic xlink:href="JIR2018-6718083.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Three-dimensional structure of the OROV polyprotein. This protein model was predicted by the I-TASSER server and visualized by the PyMOL molecular graphics system.</p></caption><graphic xlink:href="JIR2018-6718083.007"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Most potential 18 T-cell epitopes with interacting MHC-I alleles, epitope conservancy score, allergenicity, and toxicity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Epitopes</th><th align="center" rowspan="1" colspan="1">Position</th><th align="center" rowspan="1" colspan="1">Antigenicity</th><th align="center" rowspan="1" colspan="1">MHC-I alleles</th><th align="center" rowspan="1" colspan="1">Conservancy</th><th align="center" rowspan="1" colspan="1">Allergenicity</th><th align="center" rowspan="1" colspan="1">Toxicity</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TSSWGCEEY</td><td align="center" rowspan="1" colspan="1">1043&#x02013;1051</td><td align="center" rowspan="1" colspan="1">0.9867</td><td align="center" rowspan="1" colspan="1">HLA-B<sup>&#x02217;</sup>27:20, HLA-C<sup>&#x02217;</sup>03:03, HLA-A<sup>&#x02217;</sup>32:07, HLA-A<sup>&#x02217;</sup>68:23, HLA-C<sup>&#x02217;</sup>12:03, HLA-B<sup>&#x02217;</sup>40:13, HLA-A<sup>&#x02217;</sup>32:15, HLA-C<sup>&#x02217;</sup>07:01, HLA-B<sup>&#x02217;</sup>15:02, HLA-B<sup>&#x02217;</sup>15:17, HLA-B<sup>&#x02217;</sup>35:01</td><td align="center" rowspan="1" colspan="1">100.00%</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">CSMCGLIHY</td><td align="center" rowspan="1" colspan="1">48&#x02013;56</td><td align="center" rowspan="1" colspan="1">0.5400</td><td align="center" rowspan="1" colspan="1">HLA-B<sup>&#x02217;</sup>27:20, HLA-A<sup>&#x02217;</sup>68:23, HLA-C<sup>&#x02217;</sup>12:03, HLA-A<sup>&#x02217;</sup>32:07, HLA-B<sup>&#x02217;</sup>15:17, HLA-B<sup>&#x02217;</sup>40:13, HLA-B<sup>&#x02217;</sup>15:02, HLA-B<sup>&#x02217;</sup>15:01, HLA-C<sup>&#x02217;</sup>14:02, HLA-A<sup>&#x02217;</sup>32:15, HLA-B<sup>&#x02217;</sup>15:03, HLA-A<sup>&#x02217;</sup>30:02</td><td align="center" rowspan="1" colspan="1">100.00%</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">LAIDTGCLY</td><td align="center" rowspan="1" colspan="1">4&#x02013;12</td><td align="center" rowspan="1" colspan="1">0.9551</td><td align="center" rowspan="1" colspan="1">HLA-C<sup>&#x02217;</sup>03:03, HLA-C<sup>&#x02217;</sup>12:03, HLA-B<sup>&#x02217;</sup>15:17, HLA-A<sup>&#x02217;</sup>68:23, HLA-B<sup>&#x02217;</sup>35:01, HLA-A<sup>&#x02217;</sup>32:07, HLA-A<sup>&#x02217;</sup>29:02, HLA-B<sup>&#x02217;</sup>15:01, HLA-B<sup>&#x02217;</sup>15:03, HLA-B<sup>&#x02217;</sup>15:02, HLA-B<sup>&#x02217;</sup>40:13</td><td align="center" rowspan="1" colspan="1">100.00%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">SLIEICITL</td><td align="center" rowspan="1" colspan="1">34&#x02013;42</td><td align="center" rowspan="1" colspan="1">0.9867</td><td align="center" rowspan="1" colspan="1">HLA-A<sup>&#x02217;</sup>02:11, HLA-A<sup>&#x02217;</sup>32:07, HLA-A<sup>&#x02217;</sup>02:12, HLA-A<sup>&#x02217;</sup>02:16, HLA-A<sup>&#x02217;</sup>02:01, HLA-A<sup>&#x02217;</sup>68:23, HLA-A<sup>&#x02217;</sup>02:02, HLA-A<sup>&#x02217;</sup>02:50, HLA-B<sup>&#x02217;</sup>27:20, HLA-C<sup>&#x02217;</sup>03:03, HLA-A<sup>&#x02217;</sup>02:03, HLA-A<sup>&#x02217;</sup>02:06, HLA-C<sup>&#x02217;</sup>12:03, HLA-A<sup>&#x02217;</sup>02:17, HLA-B<sup>&#x02217;</sup>15:02, HLA-C<sup>&#x02217;</sup>07:02, HLA-C<sup>&#x02217;</sup>14:02, HLA-A<sup>&#x02217;</sup>02:19, HLA-A<sup>&#x02217;</sup>32:15</td><td align="center" rowspan="1" colspan="1">76.19%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">IIFALIITK</td><td align="center" rowspan="1" colspan="1">12&#x02013;20</td><td align="center" rowspan="1" colspan="1">0.7267</td><td align="center" rowspan="1" colspan="1">HLA-C<sup>&#x02217;</sup>12:03, HLA-A<sup>&#x02217;</sup>11:01, HLA-A<sup>&#x02217;</sup>32:07, HLA-B<sup>&#x02217;</sup>40:13, HLA-A<sup>&#x02217;</sup>03:01, HLA-B<sup>&#x02217;</sup>27:20, HLA-A<sup>&#x02217;</sup>68:23, HLA-A<sup>&#x02217;</sup>68:01, HLA-A<sup>&#x02217;</sup>32:15, HLA-C<sup>&#x02217;</sup>03:03, HLA-A<sup>&#x02217;</sup>30:01</td><td align="center" rowspan="1" colspan="1">80.95%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">LIHYRPGLK</td><td align="center" rowspan="1" colspan="1">53&#x02013;61</td><td align="center" rowspan="1" colspan="1">1.7718</td><td align="center" rowspan="1" colspan="1">HLA-A<sup>&#x02217;</sup>32:07, HLA-B<sup>&#x02217;</sup>27:20, HLA-C<sup>&#x02217;</sup>12:03, HLA-C<sup>&#x02217;</sup>03:03, HLA-A<sup>&#x02217;</sup>68:23, HLA-A<sup>&#x02217;</sup>30:01, HLA-A<sup>&#x02217;</sup>03:01, HLA-B<sup>&#x02217;</sup>40:13, HLA-A<sup>&#x02217;</sup>32:15</td><td align="center" rowspan="1" colspan="1">80.95%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">IFAAIIFAL</td><td align="center" rowspan="1" colspan="1">8&#x02013;16</td><td align="center" rowspan="1" colspan="1">0.6140</td><td align="center" rowspan="1" colspan="1">HLA-C<sup>&#x02217;</sup>03:03, HLA-A<sup>&#x02217;</sup>02:50, HLA-B<sup>&#x02217;</sup>27:20, HLA-A<sup>&#x02217;</sup>02:02, HLA-A<sup>&#x02217;</sup>68:23, HLA-B<sup>&#x02217;</sup>40:13, HLA-A<sup>&#x02217;</sup>32:07, HLA-A<sup>&#x02217;</sup>02:11, HLA-A<sup>&#x02217;</sup>02:06, HLA-B<sup>&#x02217;</sup>15:02, HLA-C<sup>&#x02217;</sup>14:02, HLA-B<sup>&#x02217;</sup>42:01, HLA-C<sup>&#x02217;</sup>12:03, HLA-C<sup>&#x02217;</sup>07:02, HLA-A<sup>&#x02217;</sup>32:15, HLA-A<sup>&#x02217;</sup>68:02, HLA-A<sup>&#x02217;</sup>02:17</td><td align="center" rowspan="1" colspan="1">80.95%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">NLPHVVPRY</td><td align="center" rowspan="1" colspan="1">25&#x02013;33</td><td align="center" rowspan="1" colspan="1">0.6878</td><td align="center" rowspan="1" colspan="1">HLA-B<sup>&#x02217;</sup>27:20, HLA-A<sup>&#x02217;</sup>32:07, HLA-A<sup>&#x02217;</sup>68:23, HLA-C<sup>&#x02217;</sup>12:03, HLA-A<sup>&#x02217;</sup>02:17, HLA-B<sup>&#x02217;</sup>40:13, HLA-C<sup>&#x02217;</sup>14:02, HLA-C<sup>&#x02217;</sup>07:02, HLA-A<sup>&#x02217;</sup>32:15, HLA-B<sup>&#x02217;</sup>15:02</td><td align="center" rowspan="1" colspan="1">80.95%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">NTIPAISGL</td><td align="center" rowspan="1" colspan="1">54&#x02013;62</td><td align="center" rowspan="1" colspan="1">0.7847</td><td align="center" rowspan="1" colspan="1">HLA-A<sup>&#x02217;</sup>68:23, HLA-C<sup>&#x02217;</sup>03:03, HLA-A<sup>&#x02217;</sup>68:02, HLA-A<sup>&#x02217;</sup>02:50, HLA-A<sup>&#x02217;</sup>32:07, HLA-B<sup>&#x02217;</sup>15:02, HLA-B<sup>&#x02217;</sup>27:20, HLA-A<sup>&#x02217;</sup>26:02, HLA-C<sup>&#x02217;</sup>12:03, HLA-A<sup>&#x02217;</sup>02:17, HLA-A<sup>&#x02217;</sup>02:06, HLA-A<sup>&#x02217;</sup>69:01, HLA-C<sup>&#x02217;</sup>07:02, HLA-A<sup>&#x02217;</sup>32:15, HLA-B<sup>&#x02217;</sup>15:17</td><td align="center" rowspan="1" colspan="1">80.95%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">VPRYHSIDV</td><td align="center" rowspan="1" colspan="1">30&#x02013;38</td><td align="center" rowspan="1" colspan="1">1.5628</td><td align="center" rowspan="1" colspan="1">HLA-A<sup>&#x02217;</sup>68:23, HLA-B<sup>&#x02217;</sup>27:20, HLA-C<sup>&#x02217;</sup>12:03, HLA-A<sup>&#x02217;</sup>32:07, HLA-B<sup>&#x02217;</sup>07:02, HLA-B<sup>&#x02217;</sup>42:01</td><td align="center" rowspan="1" colspan="1">80.95%</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">IPAISGLGV</td><td align="center" rowspan="1" colspan="1">56&#x02013;64</td><td align="center" rowspan="1" colspan="1">1.2054</td><td align="center" rowspan="1" colspan="1">HLA-A<sup>&#x02217;</sup>02:50, HLA-B<sup>&#x02217;</sup>27:20, HLA-A<sup>&#x02217;</sup>32:07, HLA-A<sup>&#x02217;</sup>68:23, HLA-C<sup>&#x02217;</sup>12:03, HLA-B<sup>&#x02217;</sup>42:01, HLA-B<sup>&#x02217;</sup>07:02, HLA-B<sup>&#x02217;</sup>40:13, HLA-A<sup>&#x02217;</sup>32:15</td><td align="center" rowspan="1" colspan="1">76.19%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">YLKNHNIDL</td><td align="center" rowspan="1" colspan="1">26&#x02013;34</td><td align="center" rowspan="1" colspan="1">1.7400</td><td align="center" rowspan="1" colspan="1">HLA-C<sup>&#x02217;</sup>12:03, HLA-B<sup>&#x02217;</sup>15:02, HLA-A<sup>&#x02217;</sup>02:50, HLA-A<sup>&#x02217;</sup>68:23, HLA-A<sup>&#x02217;</sup>32:07, HLA-C<sup>&#x02217;</sup>14:02, HLA-C<sup>&#x02217;</sup>03:03, HLA-B<sup>&#x02217;</sup>27:20, HLA-A<sup>&#x02217;</sup>02:12, HLA-A<sup>&#x02217;</sup>02:17, HLA-A<sup>&#x02217;</sup>02:03, HLA-C<sup>&#x02217;</sup>06:02, HLA-A<sup>&#x02217;</sup>32:15, HLA-B<sup>&#x02217;</sup>08:01, HLA-A<sup>&#x02217;</sup>02:02, HLA-C<sup>&#x02217;</sup>07:02</td><td align="center" rowspan="1" colspan="1">71.43%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">YNVAWRTYL</td><td align="center" rowspan="1" colspan="1">19&#x02013;27</td><td align="center" rowspan="1" colspan="1">0.4500</td><td align="center" rowspan="1" colspan="1">HLA-C<sup>&#x02217;</sup>03:03, HLA-A<sup>&#x02217;</sup>02:50, HLA-B<sup>&#x02217;</sup>27:20, HLA-B<sup>&#x02217;</sup>15:02, HLA-A<sup>&#x02217;</sup>68:23, HLA-A<sup>&#x02217;</sup>32:15, HLA-C<sup>&#x02217;</sup>12:03, HLA-C<sup>&#x02217;</sup>14:02, HLA-A<sup>&#x02217;</sup>32:07, HLA-A<sup>&#x02217;</sup>02:17</td><td align="center" rowspan="1" colspan="1">71.43%</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">LEPIIGDKL</td><td align="center" rowspan="1" colspan="1">54&#x02013;62</td><td align="center" rowspan="1" colspan="1">0.4388</td><td align="center" rowspan="1" colspan="1">HLA-A<sup>&#x02217;</sup>02:17, HLA-A<sup>&#x02217;</sup>02:50, HLA-C<sup>&#x02217;</sup>12:03, HLA-A<sup>&#x02217;</sup>32:07, HLA-A<sup>&#x02217;</sup>68:23, HLA-B<sup>&#x02217;</sup>40:13, HLA-B<sup>&#x02217;</sup>27:20, HLA-B<sup>&#x02217;</sup>40:01, HLA-A<sup>&#x02217;</sup>32:15, HLA-B<sup>&#x02217;</sup>15:02</td><td align="center" rowspan="1" colspan="1">80.95%</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">CEEYGCLAI</td><td align="center" rowspan="1" colspan="1">1048&#x02013;1056</td><td align="center" rowspan="1" colspan="1">1.6829</td><td align="center" rowspan="1" colspan="1">HLA-B<sup>&#x02217;</sup>27:20, HLA-C<sup>&#x02217;</sup>12:03, HLA-A<sup>&#x02217;</sup>32:07, HLA-B<sup>&#x02217;</sup>40:13, HLA-B<sup>&#x02217;</sup>40:01, HLA-A<sup>&#x02217;</sup>02:50, HLA-A<sup>&#x02217;</sup>68:23, HLA-C<sup>&#x02217;</sup>05:01, HLA-A<sup>&#x02217;</sup>32:15, HLA-C<sup>&#x02217;</sup>03:03</td><td align="center" rowspan="1" colspan="1">95.24%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Toxin</td></tr><tr><td align="left" rowspan="1" colspan="1">NSGPYNVAW</td><td align="center" rowspan="1" colspan="1">15&#x02013;23</td><td align="center" rowspan="1" colspan="1">0.8498</td><td align="center" rowspan="1" colspan="1">HLA-B<sup>&#x02217;</sup>27:20, HLA-A<sup>&#x02217;</sup>32:07, HLA-C<sup>&#x02217;</sup>12:03, HLA-B<sup>&#x02217;</sup>40:13, HLA-A<sup>&#x02217;</sup>32:15, HLA-A<sup>&#x02217;</sup>68:23, HLA-C<sup>&#x02217;</sup>07:01, HLA-C<sup>&#x02217;</sup>03:03, HLA-B<sup>&#x02217;</sup>58:01, HLA-A<sup>&#x02217;</sup>02:50, HLA-B<sup>&#x02217;</sup>57:01</td><td align="center" rowspan="1" colspan="1">80.95%</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">RQHRGCIRF</td><td align="center" rowspan="1" colspan="1">43&#x02013;51</td><td align="center" rowspan="1" colspan="1">1.0559</td><td align="center" rowspan="1" colspan="1">HLA-B<sup>&#x02217;</sup>27:20, HLA-B<sup>&#x02217;</sup>15:03, HLA-A<sup>&#x02217;</sup>32:07, HLA-B<sup>&#x02217;</sup>40:13, HLA-A<sup>&#x02217;</sup>68:23, HLA-B<sup>&#x02217;</sup>15:01, HLA-C<sup>&#x02217;</sup>12:03</td><td align="center" rowspan="1" colspan="1">71.43%</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Toxin</td></tr><tr><td align="left" rowspan="1" colspan="1">AISGLGVGY</td><td align="center" rowspan="1" colspan="1">58&#x02013;66</td><td align="center" rowspan="1" colspan="1">1.1548</td><td align="center" rowspan="1" colspan="1">HLA-A<sup>&#x02217;</sup>32:07, HLA-C<sup>&#x02217;</sup>12:03, HLA-A<sup>&#x02217;</sup>32:15, HLA-C<sup>&#x02217;</sup>03:03, HLA-A<sup>&#x02217;</sup>68:23, HLA-B<sup>&#x02217;</sup>27:20, HLA-B<sup>&#x02217;</sup>40:13, HLA-A<sup>&#x02217;</sup>30:02, HLA-B<sup>&#x02217;</sup>15:17</td><td align="center" rowspan="1" colspan="1">76.19%</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>MHC-II alleles for the desired epitope.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Core sequence</th><th align="center" rowspan="1" colspan="1">MHC-II alleles</th><th align="center" rowspan="1" colspan="1">position</th><th align="center" rowspan="1" colspan="1">Peptide</th><th align="center" rowspan="1" colspan="1">IC50 value</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">TSSWGCEEY</td><td align="center" rowspan="1" colspan="1">HLA-DQA1<sup>&#x02217;</sup>01:01/DQB1<sup>&#x02217;</sup>05:01</td><td align="center" rowspan="1" colspan="1">1040&#x02013;1054</td><td align="center" rowspan="1" colspan="1">KEHTSSWGCEEYGCL</td><td align="center" rowspan="1" colspan="1">2715</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DQA1<sup>&#x02217;</sup>01:01/DQB1<sup>&#x02217;</sup>05:01</td><td align="center" rowspan="1" colspan="1">1041&#x02013;1055</td><td align="center" rowspan="1" colspan="1">EHTSSWGCEEYGCLA</td><td align="center" rowspan="1" colspan="1">2801</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="31" colspan="1">LAIDTGCLY</td><td align="center" rowspan="1" colspan="1">HLA-DRB3<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1049&#x02013;1063</td><td align="center" rowspan="1" colspan="1">EEYGCLAIDTGCLYG</td><td align="center" rowspan="1" colspan="1">194</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB3<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1050&#x02013;1064</td><td align="center" rowspan="1" colspan="1">EYGCLAIDTGCLYGS</td><td align="center" rowspan="1" colspan="1">195</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB3<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1052&#x02013;1066</td><td align="center" rowspan="1" colspan="1">GCLAIDTGCLYGSCQ</td><td align="center" rowspan="1" colspan="1">195</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB3<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1051&#x02013;1065</td><td align="center" rowspan="1" colspan="1">YGCLAIDTGCLYGSC</td><td align="center" rowspan="1" colspan="1">196</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>03:01</td><td align="center" rowspan="1" colspan="1">1049&#x02013;1063</td><td align="center" rowspan="1" colspan="1">EEYGCLAIDTGCLYG</td><td align="center" rowspan="1" colspan="1">401</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>03:01</td><td align="center" rowspan="1" colspan="1">1050&#x02013;1064</td><td align="center" rowspan="1" colspan="1">EYGCLAIDTGCLYGS</td><td align="center" rowspan="1" colspan="1">401</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>03:01</td><td align="center" rowspan="1" colspan="1">1051&#x02013;1065</td><td align="center" rowspan="1" colspan="1">YGCLAIDTGCLYGSC</td><td align="center" rowspan="1" colspan="1">403</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>03:01</td><td align="center" rowspan="1" colspan="1">1052&#x02013;1066</td><td align="center" rowspan="1" colspan="1">GCLAIDTGCLYGSCQ</td><td align="center" rowspan="1" colspan="1">405</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB3<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1054&#x02013;1068</td><td align="center" rowspan="1" colspan="1">LAIDTGCLYGSCQDV</td><td align="center" rowspan="1" colspan="1">601</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB3<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1053&#x02013;1067</td><td align="center" rowspan="1" colspan="1">CLAIDTGCLYGSCQD</td><td align="center" rowspan="1" colspan="1">611</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>03:01</td><td align="center" rowspan="1" colspan="1">1054&#x02013;1068</td><td align="center" rowspan="1" colspan="1">LAIDTGCLYGSCQDV</td><td align="center" rowspan="1" colspan="1">1173</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>03:01</td><td align="center" rowspan="1" colspan="1">1053&#x02013;1067</td><td align="center" rowspan="1" colspan="1">CLAIDTGCLYGSCQD</td><td align="center" rowspan="1" colspan="1">1200</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>12:01</td><td align="center" rowspan="1" colspan="1">1051&#x02013;1065</td><td align="center" rowspan="1" colspan="1">YGCLAIDTGCLYGSC</td><td align="center" rowspan="1" colspan="1">1450</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>12:01</td><td align="center" rowspan="1" colspan="1">1050&#x02013;1064</td><td align="center" rowspan="1" colspan="1">EYGCLAIDTGCLYGS</td><td align="center" rowspan="1" colspan="1">1457</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DPA1<sup>&#x02217;</sup>01:03/DPB1<sup>&#x02217;</sup>02:01</td><td align="center" rowspan="1" colspan="1">1049&#x02013;1063</td><td align="center" rowspan="1" colspan="1">EEYGCLAIDTGCLYG</td><td align="center" rowspan="1" colspan="1">1545</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DPA1<sup>&#x02217;</sup>01:03/DPB1<sup>&#x02217;</sup>02:01</td><td align="center" rowspan="1" colspan="1">1051&#x02013;1065</td><td align="center" rowspan="1" colspan="1">YGCLAIDTGCLYGSC</td><td align="center" rowspan="1" colspan="1">1551</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DPA1<sup>&#x02217;</sup>01:03/DPB1<sup>&#x02217;</sup>02:01</td><td align="center" rowspan="1" colspan="1">1050&#x02013;1064</td><td align="center" rowspan="1" colspan="1">EYGCLAIDTGCLYGS</td><td align="center" rowspan="1" colspan="1">1554</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>12:01</td><td align="center" rowspan="1" colspan="1">1052&#x02013;1066</td><td align="center" rowspan="1" colspan="1">GCLAIDTGCLYGSCQ</td><td align="center" rowspan="1" colspan="1">1561</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DPA1<sup>&#x02217;</sup>01:03/DPB1<sup>&#x02217;</sup>02:01</td><td align="center" rowspan="1" colspan="1">1052&#x02013;1066</td><td align="center" rowspan="1" colspan="1">GCLAIDTGCLYGSCQ</td><td align="center" rowspan="1" colspan="1">1571</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1052&#x02013;1066</td><td align="center" rowspan="1" colspan="1">GCLAIDTGCLYGSCQ</td><td align="center" rowspan="1" colspan="1">1597</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DPA1<sup>&#x02217;</sup>02:01/DPB1<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1050&#x02013;1064</td><td align="center" rowspan="1" colspan="1">EYGCLAIDTGCLYGS</td><td align="center" rowspan="1" colspan="1">2005</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>13:02</td><td align="center" rowspan="1" colspan="1">1050&#x02013;1064</td><td align="center" rowspan="1" colspan="1">EYGCLAIDTGCLYGS</td><td align="center" rowspan="1" colspan="1">2117</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DPA1<sup>&#x02217;</sup>02:01/DPB1<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1051&#x02013;1065</td><td align="center" rowspan="1" colspan="1">YGCLAIDTGCLYGSC</td><td align="center" rowspan="1" colspan="1">2123</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>13:02</td><td align="center" rowspan="1" colspan="1">1049&#x02013;1063</td><td align="center" rowspan="1" colspan="1">EEYGCLAIDTGCLYG</td><td align="center" rowspan="1" colspan="1">2127</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>13:02</td><td align="center" rowspan="1" colspan="1">1051&#x02013;1065</td><td align="center" rowspan="1" colspan="1">YGCLAIDTGCLYGSC</td><td align="center" rowspan="1" colspan="1">2145</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DPA1<sup>&#x02217;</sup>02:01/DPB1<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1052&#x02013;1066</td><td align="center" rowspan="1" colspan="1">GCLAIDTGCLYGSCQ</td><td align="center" rowspan="1" colspan="1">2201</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DPA1<sup>&#x02217;</sup>02:01/DPB1<sup>&#x02217;</sup>01:01</td><td align="center" rowspan="1" colspan="1">1049&#x02013;1063</td><td align="center" rowspan="1" colspan="1">EEYGCLAIDTGCLYG</td><td align="center" rowspan="1" colspan="1">2287</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>04:01</td><td align="center" rowspan="1" colspan="1">1050&#x02013;1064</td><td align="center" rowspan="1" colspan="1">EYGCLAIDTGCLYGS</td><td align="center" rowspan="1" colspan="1">2673</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>12:01</td><td align="center" rowspan="1" colspan="1">1053&#x02013;1067</td><td align="center" rowspan="1" colspan="1">CLAIDTGCLYGSCQD</td><td align="center" rowspan="1" colspan="1">2760</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>12:01</td><td align="center" rowspan="1" colspan="1">1054&#x02013;1068</td><td align="center" rowspan="1" colspan="1">LAIDTGCLYGSCQDV</td><td align="center" rowspan="1" colspan="1">2917</td></tr><tr><td align="center" rowspan="1" colspan="1">HLA-DRB1<sup>&#x02217;</sup>12:01</td><td align="center" rowspan="1" colspan="1">1049&#x02013;1063</td><td align="center" rowspan="1" colspan="1">EEYGCLAIDTGCLYG</td><td align="center" rowspan="1" colspan="1">2949</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Linear B-cell epitopes of the polyprotein of OROV predicted by BepiPred-2.0.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">B-cell epitopes</th><th align="center" rowspan="2" colspan="1">Position</th><th align="center" rowspan="2" colspan="1">Antigenicity score</th><th align="center" rowspan="2" colspan="1">Conservancy (%)</th><th align="center" rowspan="2" colspan="1">Toxicity</th><th align="center" colspan="2" rowspan="1">Allergenicity</th></tr><tr><th align="center" rowspan="1" colspan="1">AllerTOP 2.0</th><th align="center" rowspan="1" colspan="1">AllergenFP 1.0</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HPLSTSQIGDRC</td><td align="center" rowspan="1" colspan="1">17&#x02013;28</td><td align="center" rowspan="1" colspan="1">1.2943</td><td align="center" rowspan="1" colspan="1">94.44</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">FKEMNLSVGL</td><td align="center" rowspan="1" colspan="1">35&#x02013;44</td><td align="center" rowspan="1" colspan="1">1.9084</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">FSKNTLALEA</td><td align="center" rowspan="1" colspan="1">62&#x02013;71</td><td align="center" rowspan="1" colspan="1">0.4645</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">VKDWSECNPVLDKL</td><td align="center" rowspan="1" colspan="1">81&#x02013;94</td><td align="center" rowspan="1" colspan="1">&#x02212;0.0129</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">SCTEALKVHRMGKDCLGYKS</td><td align="center" rowspan="1" colspan="1">282&#x02013;301</td><td align="center" rowspan="1" colspan="1">0.4510</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">AGERMYKLEELADD</td><td align="center" rowspan="1" colspan="1">334&#x02013;347</td><td align="center" rowspan="1" colspan="1">0.2927</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">IHYRPGLKVDLTK</td><td align="center" rowspan="1" colspan="1">404&#x02013;416</td><td align="center" rowspan="1" colspan="1">0.4322</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">FDEQQSSGFEYEVFLKDMHIQRESCKFGPR</td><td align="center" rowspan="1" colspan="1">427&#x02013;456</td><td align="center" rowspan="1" colspan="1">0.6740</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">DCLSKNIKITYQELH</td><td align="center" rowspan="1" colspan="1">484&#x02013;498</td><td align="center" rowspan="1" colspan="1">1.2448</td><td align="center" rowspan="1" colspan="1">11.11</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">YIMGDTCVSKSELYSDLLSKNLITEYDKKYFEPDTVN</td><td align="center" rowspan="1" colspan="1">504&#x02013;540</td><td align="center" rowspan="1" colspan="1">0.1143</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">ECEMLSLKKNSGPYN</td><td align="center" rowspan="1" colspan="1">566&#x02013;580</td><td align="center" rowspan="1" colspan="1">0.6930</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">LCSRHNY</td><td align="center" rowspan="1" colspan="1">594&#x02013;600</td><td align="center" rowspan="1" colspan="1">1.2777</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">HSMCKNTDIDFNNEIETYYKANAAAY</td><td align="center" rowspan="1" colspan="1">610&#x02013;635</td><td align="center" rowspan="1" colspan="1">0.7190</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">NISLGRSTRSAQHSIMTNEIPKSNPFTDYSYSSVNIKECMSP</td><td align="center" rowspan="1" colspan="1">699&#x02013;740</td><td align="center" rowspan="1" colspan="1">0.6399</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">KKRDSVPHT</td><td align="center" rowspan="1" colspan="1">747&#x02013;755</td><td align="center" rowspan="1" colspan="1">0.9721</td><td align="center" rowspan="1" colspan="1">11.11</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">KYKAFDWPEIETVQKGQKLCL</td><td align="center" rowspan="1" colspan="1">765&#x02013;785</td><td align="center" rowspan="1" colspan="1">1.3196</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">SHCNLEFTAITADKIMSL</td><td align="center" rowspan="1" colspan="1">788&#x02013;805</td><td align="center" rowspan="1" colspan="1">1.0518</td><td align="center" rowspan="1" colspan="1">83.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">NCYKESFTAQPADMQTGI</td><td align="center" rowspan="1" colspan="1">807&#x02013;824</td><td align="center" rowspan="1" colspan="1">0.8661</td><td align="center" rowspan="1" colspan="1">61.11</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">CITLEDKA</td><td align="center" rowspan="1" colspan="1">835&#x02013;842</td><td align="center" rowspan="1" colspan="1">2.5070</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">KYYYSDGKEHAKDGSIN</td><td align="center" rowspan="1" colspan="1">851&#x02013;867</td><td align="center" rowspan="1" colspan="1">0.6483</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">CSEQRFPIHKNWFKKCNWDKTHKEFTTMRQINYNDITSYRKAIES</td><td align="center" rowspan="1" colspan="1">875&#x02013;919</td><td align="center" rowspan="1" colspan="1">0.1740</td><td align="center" rowspan="1" colspan="1">27.78</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">GTDLMTHHYKPTKNLPHVVPRYH</td><td align="center" rowspan="1" colspan="1">922&#x02013;944</td><td align="center" rowspan="1" colspan="1">0.3102</td><td align="center" rowspan="1" colspan="1">72.22</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">AQYQKVYTTGPSISINIEHNEK</td><td align="center" rowspan="1" colspan="1">999&#x02013;1020</td><td align="center" rowspan="1" colspan="1">0.6311</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">PEKIPAKEGWLTFSKEHTSSW</td><td align="center" rowspan="1" colspan="1">1026&#x02013;1046</td><td align="center" rowspan="1" colspan="1">0.5512</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">ETYCNDMDILEPIIGD</td><td align="center" rowspan="1" colspan="1">1095&#x02013;1110</td><td align="center" rowspan="1" colspan="1">0.1167</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">TQTNQLP</td><td align="center" rowspan="1" colspan="1">1119&#x02013;1125</td><td align="center" rowspan="1" colspan="1">0.9980</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">TGQINDVGNTALQCGSIQVVNGSTIGSGNPK</td><td align="center" rowspan="1" colspan="1">1137&#x02013;1167</td><td align="center" rowspan="1" colspan="1">0.8145</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">FNDNYQSCT</td><td align="center" rowspan="1" colspan="1">1186&#x02013;1194</td><td align="center" rowspan="1" colspan="1">0.0858</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">DARNDLIPYRKG</td><td align="center" rowspan="1" colspan="1">1197&#x02013;1208</td><td align="center" rowspan="1" colspan="1">1.4056</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">DINYKIFTKSV</td><td align="center" rowspan="1" colspan="1">1231&#x02013;1241</td><td align="center" rowspan="1" colspan="1">0.3093</td><td align="center" rowspan="1" colspan="1">55.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">TVKPYNQKIDLSQLDESNYIKEEDLQCG</td><td align="center" rowspan="1" colspan="1">1322&#x02013;1349</td><td align="center" rowspan="1" colspan="1">0.8134</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr></tbody></table></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Linear B-cell epitopes of the polyprotein of OROV predicted by LBtope.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">B-cell epitopes</th><th align="center" rowspan="2" colspan="1">Position</th><th align="center" rowspan="2" colspan="1">Antigenicity scores</th><th align="center" rowspan="2" colspan="1">Conservancy (%)</th><th align="center" rowspan="2" colspan="1">Toxicity</th><th align="center" colspan="2" rowspan="1">Allergenicity</th></tr><tr><th align="center" rowspan="1" colspan="1">AllerTOP 2.0</th><th align="center" rowspan="1" colspan="1">AllergenFP 1.0</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IAYGHPLSTSQI</td><td align="center" rowspan="1" colspan="1">13&#x02013;24</td><td align="center" rowspan="1" colspan="1">0.3474</td><td align="center" rowspan="1" colspan="1">50.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">TTAFSKNTLALEAT</td><td align="center" rowspan="1" colspan="1">59&#x02013;72</td><td align="center" rowspan="1" colspan="1">0.6595</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">PRMYTCRAACDI</td><td align="center" rowspan="1" colspan="1">110&#x02013;121</td><td align="center" rowspan="1" colspan="1">&#x02212;0.5422</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">GLKVDLTKTN</td><td align="center" rowspan="1" colspan="1">409&#x02013;418</td><td align="center" rowspan="1" colspan="1">0.5124</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">SSGFEYEVFLKDMH</td><td align="center" rowspan="1" colspan="1">432&#x02013;445</td><td align="center" rowspan="1" colspan="1">0.1548</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">QRESCKFGPRVNHFRNTK</td><td align="center" rowspan="1" colspan="1">447&#x02013;464</td><td align="center" rowspan="1" colspan="1">1.1279</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">DLLSKNLITEYDKKYFEPDTVNDQFNKIEFAQD</td><td align="center" rowspan="1" colspan="1">519&#x02013;551</td><td align="center" rowspan="1" colspan="1">0.2055</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">DFNNEIETYYKANAAAYRSDFYTI</td><td align="center" rowspan="1" colspan="1">619&#x02013;642</td><td align="center" rowspan="1" colspan="1">0.1701</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">TRSAQHSIMTN</td><td align="center" rowspan="1" colspan="1">706&#x02013;716</td><td align="center" rowspan="1" colspan="1">0.1229</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">HTNHLLCKMDNKYKAFDWPEIETVQK</td><td align="center" rowspan="1" colspan="1">754&#x02013;779</td><td align="center" rowspan="1" colspan="1">1.0858</td><td align="center" rowspan="1" colspan="1">16.67</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">CITLEDKAWP</td><td align="center" rowspan="1" colspan="1">835&#x02013;844</td><td align="center" rowspan="1" colspan="1">2.0270</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">CGDKYYYSDGKEHAKDGS</td><td align="center" rowspan="1" colspan="1">848&#x02013;865</td><td align="center" rowspan="1" colspan="1">0.3358</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">KCNWDKT</td><td align="center" rowspan="1" colspan="1">889&#x02013;895</td><td align="center" rowspan="1" colspan="1">0.4951</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">HHYKPTKNLPHVVPRYH</td><td align="center" rowspan="1" colspan="1">928&#x02013;944</td><td align="center" rowspan="1" colspan="1">0.6022</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">VYTTGPSIS</td><td align="center" rowspan="1" colspan="1">1004&#x02013;1013</td><td align="center" rowspan="1" colspan="1">0.4965</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">CITLPHETYCNDMDILEPII</td><td align="center" rowspan="1" colspan="1">1089&#x02013;1108</td><td align="center" rowspan="1" colspan="1">0.2420</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">DNYQSCTRLDARNDLIPYRKG</td><td align="center" rowspan="1" colspan="1">1188&#x02013;1208</td><td align="center" rowspan="1" colspan="1">1.0163</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">CHCKTNCED</td><td align="center" rowspan="1" colspan="1">1273&#x02013;1281</td><td align="center" rowspan="1" colspan="1">1.1907</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">NQKIDLSQL</td><td align="center" rowspan="1" colspan="1">1327&#x02013;1335</td><td align="center" rowspan="1" colspan="1">0.5667</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr></tbody></table></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Most conserved B-cell epitope sequences predicted by both BepiPred-2.0 and LBtope.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">B-cell epitopes</th><th align="center" rowspan="2" colspan="1">Position</th><th align="center" rowspan="2" colspan="1">Length</th><th align="center" rowspan="2" colspan="1">Antigenicity score</th><th align="center" rowspan="2" colspan="1">Conservancy (%)</th><th align="center" rowspan="2" colspan="1">Toxicity</th><th align="center" colspan="2" rowspan="1">Allergenicity</th></tr><tr><th align="center" rowspan="1" colspan="1">AllerTOP 2.0</th><th align="center" rowspan="1" colspan="1">AllergenFP 1.0</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HPLSTSQI</td><td align="center" rowspan="1" colspan="1">17&#x02013;24</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">0.7973</td><td align="center" rowspan="1" colspan="1">94.44</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">FSKNTLALEA</td><td align="center" rowspan="1" colspan="1">62&#x02013;71</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.4645</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">GLKVDLTK</td><td align="center" rowspan="1" colspan="1">409&#x02013;416</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">&#x02212;0.8608</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">SSGFEYEVFLKDMH</td><td align="center" rowspan="1" colspan="1">432&#x02013;445</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">0.1548</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">QRESCKFGPR</td><td align="center" rowspan="1" colspan="1">447&#x02013;456</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">2.2285</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">DLLSKNLITEYDKKYFEPDTVN</td><td align="center" rowspan="1" colspan="1">519&#x02013;540</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">0.2587</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">DFNNEIETYYKANAAAY</td><td align="center" rowspan="1" colspan="1">619&#x02013;635</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">0.1778</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">TRSAQHSIMTN</td><td align="center" rowspan="1" colspan="1">706&#x02013;716</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">0.1229</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">KYKAFDWPEIETVQK</td><td align="center" rowspan="1" colspan="1">765&#x02013;779</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">1.1837</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">CITLEDKA</td><td align="center" rowspan="1" colspan="1">835&#x02013;842</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">2.5070</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">KYYYSDGKEHAKDGS</td><td align="center" rowspan="1" colspan="1">851&#x02013;865</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">0.5485</td><td align="center" rowspan="1" colspan="1">33.33</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">KCNWDKT</td><td align="center" rowspan="1" colspan="1">889&#x02013;895</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">0.4951</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">HHYKPTKNLPHVVPRYH</td><td align="center" rowspan="1" colspan="1">928&#x02013;944</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">0.6022</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">VYTTGPSIS</td><td align="center" rowspan="1" colspan="1">1004&#x02013;1013</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">0.4965</td><td align="center" rowspan="1" colspan="1">38.89</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">ETYCNDMDILEPII</td><td align="center" rowspan="1" colspan="1">1095&#x02013;1108</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">0.1553</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">DNYQSCT</td><td align="center" rowspan="1" colspan="1">1188&#x02013;1194</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">&#x02212;0.1560</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">DARNDLIPYRKG</td><td align="center" rowspan="1" colspan="1">1197&#x02013;1208</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">1.4056</td><td align="center" rowspan="1" colspan="1">5.56</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">NQKIDLSQL</td><td align="center" rowspan="1" colspan="1">1327&#x02013;1335</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">0.5667</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr></tbody></table></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Predicted conformational B-cell epitopes of the polyprotein of OROV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Epitope no.</th><th align="center" rowspan="1" colspan="1">Residues and their positions</th><th align="center" rowspan="1" colspan="1">No. of residues</th><th align="center" rowspan="1" colspan="1">Score</th><th align="center" rowspan="1" colspan="1">3D structure</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1.</td><td align="center" rowspan="1" colspan="1">V992, K993, K994, A995, V996, Y997, K998, A999, Q1000, Y1001, Q1002, K1003, V1004, T1006, T1007, G1008, P1009, S1010, I1011, S1012, I1013, N1014, I1015, E1016, H1017, N1018, E1019, K1020, C1021, T1022, G1023, H1024, C1025, P1026, E1027, K1028, I1029, P1030, A1031, K1032, E1033, G1034, W1035, L1036, T1037, K1040, E1041, S1044, S1045, W1046, G1047, C1048, E1049, E1050, Y1051, G1052, C1053, L1054, A1055, I1056, D1057, T1058, G1059, C1060, L1061, Y1062, G1063, S1064, C1065, Q1066, D1067, V1068, I1069, R1070, P1071, E1072, L1073, D1074, I1075, K1077, K1078, I1079, G1080, S1081, E1082, D1110, K1111, I1140</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">0.906</td><td align="center" rowspan="1" colspan="1">
<xref ref-type="fig" rid="fig5">Figure 5(a)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2.</td><td align="center" rowspan="1" colspan="1">Y76, R77, I80, V81, D83, W84, S85, E86, C87, N88, P89, V90, L91, D92, K93, L94, G95, N96, M98, N105, G106, H107, L108, V109, P110, R111, M112, Y113, T114, C115, R116, A117, A118, C119, D120, I121, R122, L123, N124, K125, D126, N127, A128, E129, I130, I131, L132, S133, S134, T135, K136, L137, N138, H139, F140, E141, I142, V143, G144, T145, T146, S147, T148, S149, G150, W151, F152, K153, N154</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">0.895</td><td align="center" rowspan="1" colspan="1">
<xref ref-type="fig" rid="fig5">Figure 5(b)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">3.</td><td align="center" rowspan="1" colspan="1">M738, S739, P740, S742, C760, K761, M762, D763, N764, K765, Y766, K767, A768, F769, D770, W771, P772, E773, I774, E775, T776, V777, Q778, K779, G780, Q781, K782, L783, C784, L785, G786, D787, S788, H789, C790, K810, E811, S812, F813, T814, A815, Q816, P817</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">0.875</td><td align="center" rowspan="1" colspan="1">
<xref ref-type="fig" rid="fig5">Figure 5(c)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">4.</td><td align="center" rowspan="1" colspan="1">Y563, T565, E566, C567, E568, M569, L570, S571, L572, K573, K574, N575, S576, G577, P578</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">0.864</td><td align="center" rowspan="1" colspan="1">
<xref ref-type="fig" rid="fig5">Figure 5(d)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">5.</td><td align="center" rowspan="1" colspan="1">G43, L44, G45, E46, I47, C48, V49, K50, D51, D52, I53, S54, I55</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">0.845</td><td align="center" rowspan="1" colspan="1">
<xref ref-type="fig" rid="fig5">Figure 5(e)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6.</td><td align="center" rowspan="1" colspan="1">I1385, I1388, V1389, L1390, V1394, L1395, L1396, P1397, I1398, G1399, R1400, L1401, L1402, K1403, A1404, F1405, L1406, I1407, K1408, E1412</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">0.843</td><td align="center" rowspan="1" colspan="1">
<xref ref-type="fig" rid="fig5">Figure 5(f)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">7.</td><td align="center" rowspan="1" colspan="1">M292, D295, C296, L297, G298</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">0.838</td><td align="center" rowspan="1" colspan="1">
<xref ref-type="fig" rid="fig5">Figure 5(g)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">8.</td><td align="center" rowspan="1" colspan="1">P332, I333, A334, G335, E336, R337, M338, Y339, K340, E342, E343, A345, D346, F387, N388, Y389, L390, S397, C398, S399, M400, C401, G402, L403, I404, H405, Y406, R407, P408, G409, L410, K411, V412, D413, L414, T415, K416, T417, N418, K419, C420, G421, S422</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">0.837</td><td align="center" rowspan="1" colspan="1">
<xref ref-type="fig" rid="fig5">Figure 5(h)</xref>
</td></tr></tbody></table></table-wrap><table-wrap id="tab7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Different physicochemical properties of the Oropouche virus (OROV) polyprotein.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Features</th><th align="center" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of amino acids</td><td align="center" rowspan="1" colspan="1">1420</td></tr><tr><td align="left" rowspan="1" colspan="1">Molecular weight</td><td align="center" rowspan="1" colspan="1">161275.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Theoretical pI</td><td align="center" rowspan="1" colspan="1">8.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of negatively charged residues (Asp&#x02009;+&#x02009;Glu)</td><td align="center" rowspan="1" colspan="1">151</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of positively charged residues (Arg&#x02009;+&#x02009;Lys)</td><td align="center" rowspan="1" colspan="1">161</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of atoms</td><td align="center" rowspan="1" colspan="1">22,605</td></tr><tr><td align="left" rowspan="1" colspan="1">Extinction coefficients</td><td align="center" rowspan="1" colspan="1">177,070</td></tr><tr><td align="left" rowspan="1" colspan="1">Instability index</td><td align="center" rowspan="1" colspan="1">37.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Aliphatic index</td><td align="center" rowspan="1" colspan="1">88.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Grand average of hydropathicity (GRAVY)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.138</td></tr></tbody></table></table-wrap><table-wrap id="tab8" orientation="portrait" position="float"><label>Table 8</label><caption><p>Top 10 binding pockets with binding residues, energy, and volume of OROV polyprotein.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Energy (kcal/mol)</th><th align="center" rowspan="1" colspan="1">Energy Range</th><th align="center" rowspan="1" colspan="1">Volume (&#x000c5;)</th><th align="center" rowspan="1" colspan="1">Certer X</th><th align="center" rowspan="1" colspan="1">Certer Y</th><th align="center" rowspan="1" colspan="1">Certer Z</th><th align="center" rowspan="1" colspan="1">Residues</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Gly-323, Leu-324, Leu-326, Gln-430, Gln-431, Ser-432, Ser-433, Gly-434, Phe-435, Glu-436, Phe-453, Lys-647, Thr-648, Ala-649, Phe-650, Cys-835, Ile-836, Leu-838</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Asp-750, Ser-751, Val-752, Ser-828, Asp-830, Ile-832, Gly-833, Ile-836, Thr-837, Cys-870, Leu-871, Ala-872, Asn-873, Lys-874, Glu-877, Phe-880, Pro-881, His-928, His-929, Tyr-930, Lys-931, Pro-932</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Lys-744, Cys-745, Phe-746, Lys-747, Lys-748, Leu-758, Leu-759, Cys-760, Thr-776, Gln-778, Lys-779, Gly-780, Gln-781, Lys-782, Leu-783, His-789, Phe-813</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Leu-34, Phe-35, Lys-36, Glu-37, Asn-39, Phe-178, His-179, Cys-181, Ala-264, Ser-265, Pro-267, Phe-268, Phe-281, Cys-309, Ser-311, Lys-312, Trp-314</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Phe-79, Asp-83, Glu-86, Met-98, Val-99, Leu-100, Asn-101, Val-102, Asp-103, Asn-105, Gly-106, Val-109, Tyr-113, Arg-116, Asp-120, Asp-126, Asn-127, Ala-128, Glu-129, Ile-131, Leu-132, Asn-138, Ile-142</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Ile-472, Ser-475, Phe-476, Val-581, Arg-584, Thr-585, Leu-587, Lys-588, Ala-630, Ala-632, Ala-633, Arg-636, Ser-637, Asp-638, Phe-639, Tyr-640, Thr-641</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Ser-912, Tyr-913, Ile-958, Asn-959, Gly-960, Phe-961, Ile-962, Gln-963, Cys-1301, Lys-1302, Ser-1303, Lys-1304, Lys-1324, Leu-1332, Ser-1333, Gln-1334, Phe-1364, Lys-1365, Gly-1366</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Ile-962, Gln-963, Asn-964, Thr-965, Ile-966, Lys-1304, Asn-1311, Gln-1320, Leu-1321, Thr-1322, Lys-1324, Leu-1367, Phe-1368, Ser-1369, Tyr-1413</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Tyr-661, Val-690, Leu-691, Lys-692, Phe-693, Ala-694, Leu-697, Leu-698, Ser-701, Arg-914, Lys-915, Glu-918, Ser-919, Gly-922, Thr-923</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">&#x02212;1677.27</td><td align="center" rowspan="1" colspan="1">(&#x02212;14.79, &#x02212;8.90)</td><td align="center" rowspan="1" colspan="1">156.00</td><td align="center" rowspan="1" colspan="1">123.724</td><td align="center" rowspan="1" colspan="1">99.245</td><td align="center" rowspan="1" colspan="1">115.842</td><td align="center" rowspan="1" colspan="1">Ile-255, Asn-256, Ser-257, Ser-259, Asn-260, Cys-261, Leu-262, Phe-268, Cys-271, Pro-272, Cys-283, Thr-284, Ala-286, Leu-287, His-290, Lys-310, Ser-311, Lys-312</td></tr></tbody></table></table-wrap></floats-group></article>